Fgfr gatekeeper mutant gene and drug targeting same

ABSTRACT

The present inventors successfully identified novel gatekeeper mutations for FGFR. Further, they discovered that mutant FGFR having the mutations demonstrate resistance to known FGFR inhibitors such as AZD4547, and at the same time demonstrate sensitivity to specific compounds. Mutant polypeptides having the mutations may be used as biomarkers in cancer treatment by FGFR inhibitors to prevent the development of side effects in therapy by conventional FGFR inhibitors, and to control the therapeutic mode for receiving the best therapeutic effect, thus making individualized treatment possible.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 15/108,014, filed on Jun. 24, 2016, which is the National Stage of International Application No. PCT/JP2014/084521, filed on Dec. 26, 2014, which claims the benefit of Japanese Application No. 2013-273053, filed on Dec. 27, 2013.

TECHNICAL FIELD

The present invention relates to mutant polypeptides comprising novel gatekeeper mutations; polynucleotides encoding the polypeptides; vectors comprising the polynucleotides; cells comprising the vectors; antibodies and fragments thereof that specifically bind to the polypeptides; oligonucleotide primers or oligonucleotide probes that hybridize to the polynucleotides; oligonucleotides that inhibit the expression of the polypeptides; pharmaceutical compositions comprising the antibodies or oligonucleotides; methods and kits for detecting the polynucleotides or mutant polypeptides; methods for testing whether a subject is resistant to an FGFR inhibitor based on the presence or absence of the polynucleotides or mutant polypeptides; methods for selecting cancer patients for whom an FGFR inhibitor is applicable; pharmaceutical compositions for treating cancer wherein compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof are used for administration to patients expressing the mutant polypeptides or carrying the polynucleotides; methods for treating or preventing cancer that comprise the step of administering an effective amount of compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof to patients expressing the mutant polypeptides or carrying the polynucleotides; use of compounds having FGFR inhibitory activity or pharmaceutically-acceptable salts thereof in the production of pharmaceutical compositions for cancer treatment for administration to patients expressing the mutant polypeptides or carrying the polynucleotides; compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof for use in treating or preventing patients expressing the mutant polypeptides or carrying the polynucleotides; as well as methods for identifying FGFR inhibitors, and such.

Background Art

Cancer can develop in any organ or tissue, and is highly refractory and lethal. It goes without saying that cancer is a highly cumbersome disease. Recent statistical data show that one out of every two people is diagnosed with cancer during his/her lifetime, and one out of four men and one out of six women die of cancer. Thus, cancer remains an extremely serious disease.

Fibroblast growth factor receptors (FGFRs) are kinases belonging to the receptor tyrosine kinase family. FGFR1, FGFR2, FGFR3, and FGFR4 constitute the FGFR family. The ligand is fibroblast growth factor (FGF), and 22 types of structurally similar proteins form the family.

Signals transmitted via FGFR are conveyed to the MAPK pathway or PI3K/AKT pathway. It has been reported that in cancer, signal transduction is involved in cell growth, angiogenesis, cell migration, invasion, metastasis, etc.; and FGFR is activated as a result of overexpression, gene hyper-amplification, mutation, or translocation (Non-patent Document 1). For example, it is known that for FGFR3, genetic translocation is observed in multiple myeloma (Non-patent Document 2); gene mutation is observed in bladder cancer (Non-patent Document 3); and overexpression is observed in ovarian cancer, non-small cell lung carcinoma, and hepatocellular carcinoma.

The findings described above suggest a connection between FGFR and cancer. Thus, attempts have been made to develop compounds with FGFR-inhibitory activity as anticancer agents (Non-patent Documents 4 and 5).

Currently, various molecule-targeting drugs specific to various types of kinases are commercially available. However, certain amino acid mutations in EGFR tyrosine kinase which is a target molecule of gefitinib, erlotinib, and such, have become the main cause for acquisition of resistance to gefitinib, erlotinib, and such. Such mutations are called gatekeeper (GK) mutations, and there have been reports on GK mutations in FGFR2 as well (Non-Patent Document 6).

Prior Art Documents Non-Patent Documents

[Non-patent Document 1] Cytokine & Growth Factor Reviews, 2005, 16: 139-149

[Non-patent Document 2] Blood, 2003, 101: 4569-4575

[Non-patent Document 3] Nature Genetics, 1999 Sep., 23(1): 18-20

[Non-patent Document 4] Cancer Research, 2012, 72: 2045-2056

[Non-patent Document 5] J. Med. Chem., 2011, 54: 7066-7083

[Non-patent Document 6] Neoplasia (2013), 15(8), 975-988

SUMMARY OF THE INVENTION Problems to be Solved by the Invention

The present inventors identified novel gatekeeper mutations in the FGFR gene, and also discovered that specific FGFR inhibitors have an inhibitory activity on FGFR carrying those mutations, which activity is equivalent that on FGFR not carrying the mutations.

In other words, an objective of the present invention is to provide novel antitumor agents that have high anticancer effects even for cancers with an FGFR that has acquired resistance to other FGFR inhibitors as a result of acquiring the above-mentioned mutations.

Means for Solving the Problems

To solve the above-mentioned problems, the present inventors conducted dedicated research on mutant genes that may cause gatekeeper mutations of various FGFRs, by performing crystal structure analyses on FGFRs. As a result, the inventors identified novel GK mutations (for example, the V564F mutation in SEQ ID NO: 1) and mutations corresponding to the above-mentioned GK mutations (for example, the V562L mutation in SEQ ID NO: 1) and found that FGFRs carrying these mutations demonstrated resistance to known FGFR inhibitors such as AZD4547, and at the same time, they demonstrated sensitivity to Compound A, and thus completed the present invention.

That is, the present invention specifically relates to: an FGFR mutant polypeptide comprising a novel gate keeper mutation; a polynucleotide encoding the mutant polypeptide; a vector comprising the polynucleotide; a cell comprising the vector; an antibody and a fragment thereof that specifically bind to the mutant polypeptide; oligonucleotide primers or oligonucleotide probe(s) that hybridize to the polynucleotide; an oligonucleotide that inhibits the expression of the mutant polypeptide; a method and a kit for detecting the mutant polypeptide or the polynucleotide; a pharmaceutical composition for cancer treatment characterized in being used by administering it to a patient expressing the mutant polypeptide; a method for treating or preventing cancer by administering the pharmaceutical composition to a patient expressing the mutant polypeptide; a method for selecting a patient to which the pharmaceutical composition is applicable; and a pharmaceutical composition and such for use in cancer treatment in a patient expressing the mutant polypeptide.

Basic characteristics and various embodiments of the present invention are listed below:

[1] A pharmaceutical composition for cancer treatment comprising as an active ingredient the compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition for cancer treatment is characterized in being used by administering it to a patient expressing an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7^(th) amino acid from the N terminus and/or a substitution of valine to leucine at the 5^(th) amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide, or having a polynucleotide encoding said mutant polypeptide:

wherein R₁, R₂, R₃, and R₄ each independently represents the group listed below: R₁ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_(n)Z₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃; R₂ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C2-6 alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_(n)Z₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃; or R₁ and R₂, together with an atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl, wherein the heterocyclyl or heteroaryl is optionally substituted by halogen; R₃ represents methyl; R₄ represents hydrogen; A is indole; R₅ represents C₁₋₅ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₃ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₁₋₃ alkoxy C₁₋₄ alkoxy C₁₋₄ alkyl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl C₁₋₃ alkyl, or 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, or C₁₋₆ trihydroxy alkyl which is optionally substituted by one or more groups independently selected from group Q; R₆ and R₇, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₃ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, C₁₋₆ trihydroxy alkyl, 3- to 10-membered heterocyclyl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, or cyano(C₁₋₃ alkyl); or alternatively R₆ and R₇, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; n represents 1 to 3; R₈ and R₉, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, or halogen; or alternatively R₈ and R₉, together with a carbon atom linked thereto, form a cycloaliphatic ring; Z₁ represents hydrogen, NR₁₀R₁₁, —OH, or 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q; R₁₀ and R₁₁, which can be the same or different, each represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, cyano(C₁₋₃ alkyl), or C₁₋₃ alkylsulfonyl C₁₋₄ alkyl; or alternatively R₁₀ and R₁₁, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R₁₂ and R₁₃, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, 3- to 10-membered cycloaliphatic ring, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; or alternatively R₁₂ and R₁₃, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q; R₁₄ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₅ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₆ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₇ represents hydrogen or C₁₋₄ alkyl; R₁₈ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₉ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R20 represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₁ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₂ represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl; R₂₃ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₄ represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl; R₂₅ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₆ and R₂₇, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxyl C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively R₂₆ and R₂₇, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R₂₈ and R₂₉, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxyl C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively R₂₈ and R₂₉, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R₃₀ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₃₁ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₃₂ represents C₁₋₄ alkyl or C₆₋₁₀ aryl; <group P> halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, 3- to 10-membered heterocyclylamino, —SO₂R16, —CN, —NO2, and 3- to 10-membered heterocyclyl; <group Q> halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, C₁₋₆ trihydroxy alkyl, 3- to 10-membered heterocyclyl amine, —SO₂R₁₆, —CN, —NO2, C₃₋₇ cycloalkyl, —COR₁₉, and 3- to 10-membered heterocyclyl which is optionally substituted by C₁₋₄ alkyl; [2] the pharmaceutical composition of [1], comprising as an active ingredient the compound represented by the formula below or a pharmaceutically acceptable salt thereof:

[3] an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7^(th) amino acid from the N terminus and/or a substitution of valine to leucine at the 5^(th) amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide; [4] a polynucleotide encoding the mutant polypeptide of [3]; [5] a vector comprising the polynucleotide of [4]; [6] a recombinant cell comprising the vector of [5]; [7] an antibody, or antigen-binding fragment thereof, that specifically binds to the mutant polypeptide of [3]; [8] a pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of [3] for detecting or amplifying the polynucleotide; [9] an oligonucleotide that binds to an mRNA polynucleotide encoding the mutant polypeptide of [3] and has an activity to inhibit translation of the mRNA polynucleotide into protein; [10] the oligonucleotide of [9], which is an siRNA that cleaves the mRNA polynucleotide; [11] a method for detecting an FGFR mutant polypeptide, which comprises the step of detecting the mutant polypeptide in a sample isolated from a subject by using an antibody, or antigen-binding fragment thereof, that specifically binds to the mutant polypeptide of [3]; [12] a method for detecting a polynucleotide encoding an FGFR mutant polypeptide, which comprises the step of detecting a polynucleotide encoding the mutant polypeptide in a sample isolated from a subject by using a pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of [3] for detecting or amplifying the polynucleotide; [13] a kit for detecting a polynucleotide encoding an FGFR mutant polypeptide, which comprises a pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of [3] for detecting or amplifying the polynucleotide; [14] a kit for detecting an FGFR mutant polypeptide, which comprises an antibody or antigen-binding fragment thereof that specifically binds to the mutant polypeptide of [3]; [15] a method for treating cancer, which comprises determining the presence or absence of the mutant polypeptide of [3] or a polynucleotide encoding the mutant polypeptide in a sample isolated from a subject and administering the pharmaceutical composition of [1] or [2] to the subject when the mutant polypeptide or the polynucleotide is detected; [16] the method of [15], wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell carcinoma, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer; [17] a method for selecting a patient to which the pharmaceutical composition of [1] or [2] is applicable, which comprises the steps of:

(a) determining the presence or absence of the mutant polypeptide of [3] in a sample isolated from a subject; and

(b) selecting a subject confirmed to have the mutant polypeptide as a patient to which the pharmaceutical composition is applicable;

[18] a method for selecting a patient to which the pharmaceutical composition of [1] or [2] is applicable, which comprises the steps of:

(a) determining the presence or absence of a polynucleotide encoding the mutant polypeptide of [3] in a sample isolated from a subject; and

(b) selecting a subject confirmed to have a polynucleotide encoding the mutant polypeptide as a patient to which the pharmaceutical composition is applicable;

[19] the method of [18], wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell carcinoma, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer; [20] the compound defined in[1] or [2] or a pharmaceutically acceptable salt thereof for use in cancer treatment in a patient who expresses the mutant polypeptide of [3] or has a polynucleotide encoding the mutant polypeptide; [21] the compound of [20] or a pharmaceutically acceptable salt thereof, wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell cancer, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer; [22] a pharmaceutical composition for cancer treatment comprising as an active ingredient the compound represented by the formula below or a pharmaceutically acceptable salt thereof, wherein the cancer expresses an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7^(th) amino acid from the N terminus and/or a substitution of valine to leucine at the 5^(th) amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide:

[23] a pharmaceutical composition for cancer treatment comprising as an active ingredient a substance that inhibits the function or expression of an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7^(th) amino acid from the N terminus and/or a substitution of valine to leucine at the 5^(th) amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide; [24] use of the compound defined in the aforementioned [1] or [2] or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for treating or preventing cancer which is to be administered to a patient expressing the mutant polypeptide of [3] or has a polynucleotide encoding the mutant polypeptide; [25] a method for detecting resistance to an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171, which comprises the steps of: (a) determining the presence or absence of the mutant polypeptide of [3] or a polynucleotide encoding the mutant polypeptide in a sample isolated from a subject; and (b) determining that the subject confirmed to have the mutant polypeptide or the polynucleotide has resistance to the FGFR inhibitor; [26] the antibody or antigen-binding fragment thereof of [7], or the oligonucleotide primers or oligonucleotide probe(s) of [8] for use in detecting resistance to an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171; [27] use of the antibody or antigen-binding fragment thereof of [7], or the oligonucleotide primers or oligonucleotide probe(s) of [8] for detecting resistance to an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171; [28] a method for predicting the response of a cancer patient to treatment by an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171, which comprises the steps of: (a) determining the presence or absence of the mutant polypeptide of [3] or a polynucleotide encoding the mutant polypeptide in a sample isolated from the patient; and (b) determining that the patient confirmed to have the mutant polypeptide or the polynucleotide has low sensitivity to the FGFR inhibitor; [29] the antibody or antigen-binding fragment thereof of [7], or the oligonucleotide primers or oligonucleotide probe(s) of [8] for use in predicting the response of a cancer patient to treatment by an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171; [30] use of the antibody or antigen-binding fragment thereof of [7], or the oligonucleotide primers or oligonucleotide probe(s) of [8] for predicting the response of a cancer patient to treatment by an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171; [31] a kit for predicting an effect of an FGFR inhibitor in cancer treatment, which comprises the antibody or antigen-binding fragment thereof of [7], or the oligonucleotide primers or oligonucleotide probe(s) of [8]; and [32] The kit of [31], wherein the FGFR inhibitor is selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171.

Effects of the Invention

The present invention can provide novel antitumor agents that have high anticancer effects on cancers with an FGFR which has acquired resistance to other FGFR inhibitors.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the effects of Compounds A and C on tyrosine phosphorylation of FGFR in cells made to express the wild-type FGFR2, the FGFR2 V564F mutant, or the FGFR2 V562L mutant.

FIG. 2 shows graphs indicating the inhibitory effects of Compounds A, B, and C on proliferation of cells made to express the wild-type FGFR2, the FGFR2 V564F mutant, or the FGFR2 V562L mutant.

FIG. 3 shows graphs indicating the inhibitory effects of Compounds A, B, C, D, and E on proliferation of cells made to express the TEL-fused wild-type FGFR2 or the TEL-fused FGFR2 V564F mutant.

FIG. 4 shows graphs indicating the inhibitory effects of Compounds A and C on tumor proliferation in mice carrying tumor cells expressing the TEL-fused wild-type FGFR2 or the TEL-fused FGFR2 V564F mutant.

FIG. 5 shows graphs indicating the inhibitory effects of Compound A or C on phosphorylation in tumors in mice carrying tumor cells expressing the TEL-fused wild-type FGFR2 or the TEL-fused FGFR2 V564F mutant.

MODE FOR CARRYING OUT THE INVENTION

The present invention is an invention illustratively described in the above-mentioned [1] to [31] and provides: an FGFR mutant polypeptide comprising a novel gate keeper mutation; a polynucleotide encoding the mutant polypeptide; a vector comprising the polynucleotide; a cell comprising the vector; an antibody and a fragment thereof that specifically bind to the mutant polypeptide; oligonucleotide primers or oligonucleotide probe(s) that hybridize to the polynucleotide; an oligonucleotide that inhibits the expression of the mutant polypeptide; a method and a kit for detecting the mutant polypeptide or the polynucleotide; a pharmaceutical composition for cancer treatment characterized in being used by administering it to a patient expressing the mutant polypeptide; a method for treating or preventing cancer by administering the pharmaceutical composition to a patient expressing the mutant polypeptide; a method for selecting a patient to which the pharmaceutical composition is applicable; a compound having

FGFR inhibitory activity or a pharmaceutically-acceptable salt thereof for use in treating or preventing cancer in a patient expressing the mutant polypeptide; use of a compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for treating or preventing cancer for administration to a patient expressing the mutant polypeptide; a method for detecting resistance to an FGFR inhibitor; a method for predicting response of a cancer patient to treatment using an FGFR inhibitor; and such.

In the present invention, “FGFR” refers to any FGFR belonging to the FGFR family comprising FGFR1, FGFR2, FGFR3, and FGFR4, which are fibroblast growth factor receptors (FGFRs) belonging to the receptor tyrosine kinase family (Cytokine & Growth Factor Reviews, 2005, 16: 139-149). FGFRs of the present invention may be of any origin, and are preferably FGFRs derived from mammals (humans, mice, rats, guinea pigs, rabbits, sheep, monkeys, goats, donkeys, bovines, horses, pigs, etc.), more preferably human FGFRs, and still more preferably human FGFR2, human FGFR1, FGFR3, each of them are known to have many isoforms.

In the present invention, “human FGFR2” is a wild-type human FGFR2 polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, 2, 37, 38, 39, 40, 41, 42, 43, or 44 (GenBank Accession No: NP_000132.3, NP_075259.4, NP_001138385.1, NP_001138386.1, NP_001138387.1, NP_001138388.1, NP_001138389.1, NP_001138390.1, NP_001138391.1, or NP_075418.1, respectively), or a mutant polypeptide with one or more (preferably one to ten, and particularly preferably one to five) amino acids being substituted, deleted, or inserted in the wild-type polypeptide.

In the present invention, “human FGFR1” is a wild-type human FGFR1 polypeptide consisting of the amino acid sequence of SEQ ID NO: 21, 45, 46, 47, 48, 49, or 50 (GenBank Accession No: NP_001167538.1, NP_001167534.1, NP_001167535.1, NP_001167536.1, NP_001167537.1, NP_075594.1, or NP_075598.2, respectively), or a mutant polypeptide with one or more (preferably one to ten, and particularly preferably one to five) amino acids being substituted, deleted, or inserted in the wild-type polypeptide.

In the present invention, “human FGFR3” is a wild-type human FGFR3 polypeptide consisting of the amino acid sequence of SEQ ID NO: 22, 51, or 52 (GenBank Accession No: NP_000133.1, NP_001156685.1, or NP_075254.1, respectively), or a mutant polypeptide with one or more (preferably one to ten, and particularly preferably one to five) amino acids being substituted, deleted, or inserted in the wild-type polypeptide. The mutant polypeptides also include polypeptides having 70% or greater homology, preferably polypeptides having 80% or greater homology, more preferably polypeptides having 90% or greater homology, and even more preferably polypeptides having 95% or greater homology to the amino acid sequence of the wild-type polypeptide.

Amino acid sequence (or nucleotide sequence) identity can be determined using the BLAST algorithm by Karlin and Altschul (Proc. Natl. Acad. Sci. USA (1993) 90, 5873-7). Programs such as BLASTN and BLASTX were developed based on this algorithm (Altschul et al., J. Mol. Biol. (1990) 215, 403-10). To analyze nucleotide sequences according to BLASTN based on BLAST, the parameters are set to, for example, score=100 and wordlength=12. On the other hand, parameters used for the analysis of amino acid sequences by BLASTX based on BLAST include, for example, score=50 and wordlength=3. Default parameters for each program are used when using the BLAST and Gapped BLAST programs. Specific techniques for such analyses are known in the art (one can refer to the information on the website of the National Center for Biotechnology Information (NCBI), Basic Local Alignment Search Tool (BLAST)).

In the present invention, “mutant polypeptide” refers to an FGFR mutant polypeptide containing a substitution of valine to phenylalanine at the 7^(th) amino acid from the N terminus and/or a substitution of valine to leucine at the 5^(th) amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in the FGFR polypeptide, and it may be also called as a polypeptide containing a mutation of the present invention.

The mutant polypeptide of the present invention is not limited to a FGFR mutant polypeptide consisting of an amino acid sequence in which an above-mentioned mutations are introduced into the amino acid sequence of the wild-type FGFR polypeptide consisting of the above-mentioned full-length amino acid sequence, as long as it is an FGFR mutant polypeptide carrying at least one of the two mutations described above. In addition, the mutant polypeptide includes peptide fragments thereof that contain the mutations, and fused polypeptides formed by fusing such FGFR mutant polypeptides or peptide fragments with other peptides, and the mutant polypeptide may also have one or more (preferably one to ten, and particularly preferably one to five) amino acid substitutions, deletions, additions, or insertions at positions other than the positions of the above-mentioned mutations.

“Other peptide” which constitute the fusion polypeptides with the FGFR mutant polypeptides or peptide fragments thereof include the TEL (also called ETV6; see Cancer Research, 2001, 61: 8371-8374 and Blood, 2005, 105(5): 2115-2123) polypeptide (a wild-type polypeptide consisting of the amino acid sequence of SEQ ID NO: 33 or mutant polypeptides with one or more amino acids being substituted, deleted, added, or inserted in the wild-type polypeptide, or peptide fragments thereof), the BAIA2P2L1 polypeptide (a wild-type polypeptide consisting of the amino acid sequence of SEQ ID NO: 31 or mutant polypeptides with one or more amino acids being substituted, deleted, added, or inserted in the wild-type polypeptide, or peptide fragments thereof), and the TACC3 polypeptide (a wild-type polypeptide consisting of the amino acid sequence of SEQ ID NO: 32 or mutant polypeptides with one or more amino acids being substituted, deleted, added, or inserted in the wild-type polypeptide, or peptide fragments thereof). A number of other FGFR fusion polypeptides are also known (see, Cancer Discovery 2013; 3: 636-647), and FGFR fusion polypeptides produced by introducing the mutations of the present invention to these fusion polypeptides are also included in the mutant polypeptides of the present invention.

Preferably, mutant polypeptides of the present invention refers to the FGFR mutant polypeptides selected from (1) to (20) shown below, peptide fragments of (1) to (20) containing those mutations, or fusion polypeptides formed by fusing the FGFR mutant polypeptides of (1) to (20) or peptide fragments thereof with other peptides:

(1) an FGFR2 mutant polypeptide containing at least the V564F and/or V562L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 1); (2) an FGFR2 mutant polypeptide containing at least the V565F and/or V563L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 2); (3) an FGFR2 mutant polypeptide containing at least the V565F and/or V563L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 37); (4) an FGFR2 mutant polypeptide containing at least the V452F and/or V450L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 38); (5) an FGFR2 mutant polypeptide containing at least the V475F and/or V473L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 39); (6) an FGFR2 mutant polypeptide containing at least the V449F and/or V447L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 40); (7) an FGFR2 mutant polypeptide containing at least the V448F and/or V446L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 41); (8) an FGFR2 mutant polypeptide containing at least the V447F and/or V445L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 42); (9) an FGFR2 mutant polypeptide containing at least the V476F and/or V474L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 43); (10) an FGFR2 mutant polypeptide containing at least the V475F and/or V473L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 44); (11) an FGFR1 mutant polypeptide containing at least the V559F and/or V557L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 21); (12) an FGFR1 mutant polypeptide containing at least the V559F and/or V557L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 45); (13) an FGFR1 mutant polypeptide containing at least the V551F and/or V549L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 46); (14) an FGFR1 mutant polypeptide containing at least the V559F and/or V557L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 47); (15) an FGFR1 mutant polypeptide containing at least the V472F and/or V470L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 48); (16) an FGFR1 mutant polypeptide containing at least the V470F and/or V468L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 49); (17) an FGFR1 mutant polypeptide containing at least the V561F and/or V559L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 50); (18) an FGFR3 mutant polypeptide containing at least the V555F and/or V553L mutations in the amino acid sequence of the above-mentioned wild-type FGFR3 polypeptide (SEQ ID NO: 22); (19) an FGFR3 mutant polypeptide containing at least the V557F and/or V555L mutations in the amino acid sequence of the above-mentioned wild-type FGFR3 polypeptide (SEQ ID NO: 51); or (20) an FGFR3 mutant polypeptide containing at least the V443F and/or V441L mutations in the amino acid sequence of the above-mentioned wild-type FGFR3 polypeptide (SEQ ID NO: 52).

Particularly preferably, the FGFR mutant polypeptides of the present invention are, for example, an FGFR2 mutant polypeptide comprising the amino acid sequence of SEQ ID NO: 9, 10, 29, or 30; an FGFR1 mutant polypeptide comprising the amino acid sequence of SEQ ID NO: 25 or 26; and an FGFR3 mutant polypeptide comprising the amino acid sequence of SEQ ID NO: 27 or 28; as well as a TEL-fused FGFR2 mutant polypeptide comprising the amino acid sequence of SEQ ID NO: 35 or 36.

Preferably, the FGFR mutant polypeptides of the present invention retain biological activities (for example, tyrosine phosphorylation activity on the intracellular domain of FGFR, cell proliferation activity, angiogenic activity, cell migration activity, cell infiltration activity, and cell transfer activity, preferably cell proliferation activity) that are the same in degree or stronger than those of the wild-type FGFR polypeptide. Whether the FGFR mutant polypeptide of the present invention has such biological activities can be determined by assay methods known to those skilled in the art (for example, by methods described in the following Examples).

Polynucleotides of the present invention include polynucleotides encoding an FGFR mutant polypeptide of the present invention described above, which include any polynucleotide that can encode an FGFR mutant polypeptide of the present invention. The polynucleotides include genomic DNAs and cDNAs. Genomic DNAs include exons and introns. Furthermore, the cDNAs may include nucleic acid sequences derived from a portion of an intron sequence that encodes amino acid sequence.

The polynucleotides also include degenerate polynucleotides constituted with any codon as long as the codon encodes the same amino acids.

The polynucleotides of the present invention also include polynucleotides encoding mutant polypeptides derived from mammals. In a preferred embodiment, the polynucleotides of the present invention include polynucleotides encoding mutant polypeptides derived from humans.

The polynucleotides of the present invention may be obtained by any methods. The polynucleotides of the present invention include, for example, all complementary DNAs (cDNAs) prepared from mRNAs, DNAs prepared from genomic DNA, DNAs obtained by chemical synthesis, DNAs obtained by PCR amplification using RNA or DNA as template, and DNAs constructed by appropriately combining these methods.

Polynucleotides encoding mutant polypeptides of the present invention can be obtained using routine methods by cloning cDNA from mRNA encoding a mutant polypeptide of the present invention or isolating genomic DNA and subjecting it to splicing treatment, or by chemical synthesis.

For example, in a method that clones cDNA from mRNA encoding a mutant polypeptide of the present invention, first, mRNA encoding a mutant polypeptide of the present invention is prepared from arbitrary tissues or cells expressing and producing the mutant polypeptide of the present invention according to routine methods. This may be achieved, for example, by preparing total RNA using a method such as the guanidine-thiocyanate method, hot phenol method, or AGPC method, and treating the total RNA with affinity chromatography using oligo(dT) cellulose, poly U-Sepharose, or the like.

Then, cDNA strand synthesis is carried out using the prepared mRNA as template by a known method that uses, for example, reverse transcriptase (Mol. Cell. Biol., Vol. 2, p. 161, 1982; Mol. Cell. Biol., Vol. 3, p. 280, 1983; Gene, Vol. 25, p. 263, 1983). The cDNA is converted to double-stranded cDNA, and inserted into a plasmid vector, phage vector, cosmid vector, or such. To prepare a cDNA library, the resulting vector is transformed into E. coli, or transfected into E. coli after in vitro packaging.

The present invention also relates to vectors (recombinant vectors) carrying the above-described polynucleotide encoding a mutant polypeptide of the present invention.

The vectors of the present invention are not particularly limited as long as they can replicate and maintain or self-propagate in various prokaryotic and/or eukaryotic cells as a host. The vectors of the present invention include plasmid vectors and phage vectors.

Cloning vectors include, for example, pUC19, λgt10, and λgt11. When isolating host cells capable of expressing a mutant polypeptide of the present invention, preferably the vector is one that has a promoter which enables expression of the polynucleotide of the present invention.

Recombinant vectors of the present invention can be prepared using routine methods simply by ligating a polynucleotide encoding a mutant polypeptide of the present invention to a recombinant vector available in the art (plasmid DNA and bacteriophage DNA).

Recombinant vectors for use in the present invention include, for example, E. coli-derived plasmids (pBR322, pBR325, pUC12, pUC13, pUC19, etc.), yeast-derived plasmids (pSH19, pSH15, etc.), and Bacillus subtilis-derived plasmids (pUB110, pTPS, pC194, etc.).

Examples of phages are bacteriophages such as λ phage, and animal or insect viruses (pVL1393, Invitrogen) such as retrovirus, vaccinia virus, nuclear polyhedrosis virus, and lentivirus.

Expression vectors are useful for the purpose of producing a mutant polypeptide of the present invention by expressing a polynucleotide encoding the mutant polypeptide of the present invention. Expression vectors are not particular limited as long as they have the function of producing mutant polypeptides of the present invention by expressing polynucleotides encoding the polypeptides in various prokaryotic and/or eukaryotic cells as a host.

Such expression vectors include, for example, pMAL C2, pEF-BOS (Nucleic Acid Research, Vol. 18, 1990, p. 5322) and pME18S (Jikken Igaku Bessatsu (Experimental Medicine: SUPPLEMENT), “Idenshi Kougaku Handbook (Handbook of Genetic Engineering)” (1992)).

Alternatively, mutant polypeptides of the present invention may be produced as fusion proteins with other proteins. For example, when preparing as a fusion protein with glutathione S-transferase (GST), cDNA encoding a mutant polypeptide of the present invention can be subcloned into, for example, plasmid pGEX4T1 (Pharmacia). E. coli DH5α is transformed with the resulting plasmid, and the transformants are cultured to prepare the fusion protein.

Alternatively, fusion polypeptides of the present invention may be produced as fusions with influenza hemagglutinin (HA), immunoglobulin constant region, β-galactosidase, maltose-binding protein (MBP), or such. Furthermore, fusion polypeptides of the present invention may be produced as fusions with known peptides, for example, FLAG (Hopp, T. P. et al., BioTechnology (1988) 6, 1204-1210), 6×His consisting of 6 histidine (His) residues, 10×His, influenza hemagglutinin (HA), fragments of human c-myc, fragments of VSV-GP, fragments of p18HIV, T7-tag, HSV-tag, E-tag, fragments of SV4OT antigen, lck tag, fragments of a-tubulin, B-tag, fragments of Protein C, Stag, StrepTag, and HaloTag.

When using bacteria, in particular E coli., as a host cell, vectors of the present invention preferably contain at least a promoter-operator region, a start codon, a polynucleotide encoding a mutant polypeptide of the present invention, a stop codon, a terminator region, and a replicon.

When yeast, animal cells, or insect cells are used as a host, expression vectors preferably contain a promoter, a start codon, a polynucleotide encoding a mutant polypeptide of the present invention, and a stop codon.

The vectors may also contain DNA encoding a signal peptide, an enhancer sequence, 5′ and 3′ untranslated regions of the gene encoding a protein of the present invention, splice junctions, polyadenylation sites, a selection marker region, a replicon, and such.

Furthermore, if necessary, the vectors may contain marker genes (genes for gene amplification, drug resistance genes, etc.) that enable selection of transformed hosts or hosts with gene amplification.

Marker genes include, for example, the dihydrofolate reductase (DHFR) gene, thymidine kinase gene, neomycin resistance gene, glutamate synthase gene, adenosine deaminase gene, ornithine decarboxylase gene, hygromycin-B-phosphotransferase gene, and aspartate transcarbamylase gene.

A promoter-operator region for expressing the mutant polypeptide of the present invention in bacteria comprises a promoter, an operator, and a Shine-Dalgarno (SD) sequence (for example, AAGG).

For example, when the host is the genus Escherichia, it comprises, for example, the Trp promoter, lac promoter, recA promoter, λPL promoter, lpp promoter, tac promoter, or such.

Examples of a promoter for expressing the mutant polypeptide of the present invention in yeast are the PH05 promoter, PGK promoter, GAP promoter, ADH promoter, and such.

When the host is Bacillus, examples are the SL01 promoter, SP02 promoter, penP promoter, and such.

When the host is a eukaryotic cell such as a mammalian cell, examples are an SV40-derived promoter, retrovirus promoter, heat shock promoter, and such; and SV40 and retrovirus are preferred. Nevertheless, the promoter is not limited to the above examples. In addition, use of an enhancer is effective for expression.

A preferable initiation codon is, for example, a methionine codon (ATG). A commonly used termination codon (for example, TAG, TAA, TGA) is exemplified as a termination codon. Commonly used natural or synthetic terminators are used as a terminator region.

A replicon refers to a DNA capable of replicating the whole DNA sequence in host cells, and includes a natural plasmid, an artificially modified plasmid (DNA fragment prepared from a natural plasmid), a synthetic plasmid, and such. Examples of preferable plasmids for E. coli are pBR322 or its artificial derivatives (DNA fragment obtained by treating pBR322 with appropriate restriction enzymes), for yeast are yeast 2μ plasmid or yeast chromosomal DNA, and pRSVneo ATCC 37198, and for mammalian cells are plasmid pSV2dhfr ATCC 37145, plasmid pdBPV-MMTneo ATCC 37224, plasmid pSV2neo ATCC 37149, and such.

An enhancer sequence, polyadenylation site, and splicing junction that are usually used in the art, such as those derived from SV40 can also be used.

The expression vector of the present invention can be prepared by continuously and circularly linking at least the above-mentioned promoter, initiation codon, polynucleotide encoding the mutant polypeptide of the present invention, termination codon, and terminator region, to an appropriate replicon. If desired, appropriate DNA fragments (for example, linkers, restriction sites, and such), can be used by a common method such as restriction enzyme digestion or ligation using T4 DNA ligase.

The present invention also relates to recombinant cells transformed with the above-mentioned vectors of the present invention, and recombinant cells of the present invention can be prepared by introducing the expression vector mentioned above into host cells.

Host cells used in the present invention are not particularly limited as long as they are compatible with an expression vector mentioned above and can be transformed. Examples thereof include various cells such as wild-type cells or artificially established recombinant cells commonly used in the technical field of the present invention (for example, bacteria (the genera Escherichia and Bacillus), yeast (the genus Saccharomyces, the genus Pichia, and such), animal cells, or insect cells).

E. coli or animal cells are preferred. Specific examples are E. coli (DH5α, TB1, HB101, and such), mouse-derived cells (COP, L, C127, Sp2/0, NS-1, NIH3T3, and such), rat-derived cells (PC12, PC12h), hamster-derived cells (BHK, CHO, and such), monkey-derived cells (COS1, COS3, COS7, CV1, Velo, and such), and human-derived cells (Hela, diploid fibroblast-derived cells, myeloma cells, and HepG2, and such).

An expression vector can be introduced (transformed (transfected)) into host cells according to routine methods.

[when the host is E. coli, Bacillus subtilis, or such]: Proc. Natl. Acad. Sci. USA, Vol. 69, p. 2110 (1972); Mol. Gen. Genet., Vol. 168, p. 111 (1979); J. Mol. Biol., Vol. 56, p. 209 (1971); [when the host is Saccharomyces cerevisiae]: Proc. Natl. Acad. Sci. USA, Vol. 75, p. 1927 (1978); J. Bacteriol., Vol. 153, p. 163 (1983); [when the host is an animal cell]: Virology, Vol. 52, p. 456 (1973); [when the host is an insect cell]: Mol. Cell. Biol., Vol. 3, pp. 2156-2165 (1983).

Mutant polypeptides of the present invention can be produced by culturing transformed recombinant cells (hereinafter, the term also refers to inclusion bodies) comprising an expression vector prepared as described above in nutritive media according to routine methods.

Mutant polypeptides of the present invention can be produced by culturing the above-described recombinant cells, in particular animal cells, and allowing them to secrete into culture supernatants.

The resulting culture is filtered or centrifuged to obtain a culture filtrate (supernatant). Mutant polypeptides of the present invention are purified and isolated from the culture filtrate by routine methods commonly used to purify and isolate natural or synthetic proteins. Examples of an isolation and purification method are methods that utilize solubility such as the salting out and solvent precipitation methods; methods that utilize difference in molecular weight such as dialysis, ultrafiltration, gel filtration, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis; methods that utilize charge such as ion exchange chromatography and hydroxylapatite chromatography; method that utilize specific affinity such as affinity column chromatography; methods that utilize difference in hydrophobicity such as reverse phase high performance liquid chromatography; and methods that utilize difference in the isoelectric point such as isoelectric focusing.

Meanwhile, when a mutant polypeptide of the present invention is in the periplasm or cytoplasm of cultured recombinant cells (such as E. coli), the cells are collected by routine methods such as filtration and centrifugation of the culture, and then suspended in an appropriate buffer. After the cell wall and/or cell membrane of the cells are disrupted using methods such as sonication, lysozyme, and cryolysis, a membrane fraction containing the protein of the present invention is obtained using methods such as centrifugation and filtration. The membrane fraction is solubilized with a detergent such as Triton-X100 to obtain the crude solution. Then, the protein of the present invention can be isolated and purified from the crude solution using routine methods such as those exemplified above.

The present invention also relates to arbitrary oligonucleotides that hybridize to polynucleotides (cDNAs and genomic DNAs) encoding the above-described mutant polypeptides of the present invention.

Oligonucleotides of the present invention have nucleotide sequences that are complementary to arbitrary partial nucleotide sequences of the cDNAs and genomic DNAs, and which are useful as a pair of oligonucleotide primers consisting of sense and antisense primers in polymerase chain reaction (PCR). The whole nucleotide sequence of a polynucleotide encoding a mutant polypeptide of the present invention or an arbitrary portion of the nucleotide sequence can be amplified by PCR using the pair of oligonucleotide primers.

Oligonucleotide primers of the present invention include oligonucleotides of any length that are complementary to the nucleotide sequence of a polynucleotide of the present invention. The oligonucleotide primers of the present invention preferably include those having a sequence of at least 12 consecutive nucleotides, more preferably 12 to 50 nucleotides, and still more preferably 12 to 20 nucleotides.

Oligonucleotides of the present invention are also useful as a probe when handling DNA or RNA hybridization. When used as a probe, the DNAs include a partial nucleotide sequence of 15 or more consecutive nucleotides, preferably a partial nucleotide sequence of 50 or more consecutive nucleotides, more preferably a partial nucleotide sequence of 100 or more consecutive nucleotides, even more preferably a partial nucleotide sequence of 200 or more consecutive nucleotides, and still more preferably a partial nucleotide sequence of 300 or more consecutive nucleotides, which hybridize to a polynucleotide of the present invention.

The present invention also relates to oligonucleotides that bind to mRNA polynucleotides encoding mutant polypeptides of the present invention and have an activity of inhibiting translation of the mRNAs into proteins. It is particularly preferable that the oligonucleotides include siRNAs that cleave the mRNAs by binding to the mRNA polynucleotides encoding mutant polypeptides of the present invention.

The oligonucleotides refer to those which bind to mRNAs encoding mutant polypeptides of the present invention and thereby inhibit their expression and include, for example, antisense oligonucleotides, ribozymes, and short interfering RNAs (siRNA). They bind to the mRNAs and then inhibit their translation into proteins.

An antisense oligonucleotide refers to an oligonucleotide that specifically hybridizes to genomic DNA and/or mRNA, and inhibits their protein expression by inhibiting the transcription and/or translation.

The binding to a target polynucleotide (mRNA, etc.) may be a result of common base pair complementarity. Alternatively, when an antisense oligonucleotide binds to, for example, a DNA duplex, the binding may be a result of specific interaction at the major grooves in double helix. Target sites for an antisense oligonucleotide include the 5′ end of an mRNA, for example, 5′ untranslated sequences up to or including the AUG start codon, and 3′ untranslated sequences of an mRNA, as well as coding region sequences.

When using as an antisense oligonucleotide of the present invention, antisense oligonucleotides include partial nucleotide sequences of 5 to 100 consecutive nucleotides, preferably partial nucleotide sequences of 5 to 70 consecutive nucleotides, more preferably partial nucleotide sequences of 5 to 50 consecutive nucleotides, and still more preferably partial nucleotide sequences of 5 to 30 consecutive nucleotides.

Furthermore, antisense oligonucleotides of the present invention can be partially modified by chemical modification to prolong their half-life in blood (to stabilize them) or increase their intracellular membrane permeability when administered to patients, or to enhance their resistance to degradation or absorption in the digestive organs in oral administration. Such chemical modification includes, for example, chemical modification of a phosphate bond, ribose, nucleobase, sugar moiety in oligonucleotides, and 3′ and/or 5′ ends of oligonucleotides.

The modification of phosphate bonds includes, for example, conversion of one or more of the bonds to phosphodiester bonds (D-oligo), phosphorothioate bonds, phosphorodithioate bonds (S-oligo), methyl phosphonate (MP-oligo), phosphoroamidate bonds, non-phosphate bonds and methyl phosphonothioate bonds, and combinations thereof. The modification of ribose includes, for example, conversion to 2′-fluororibose or 2′-O-methylribose. The modification of nucleotide base includes, for example, conversion to 5-propynyluracil or 2-aminoadenine.

Ribozyme refers to oligonucleotides having a catalytic activity of cleaving mRNA. In general, ribozymes have endonuclease, ligase, or polymerase activity. Ribozymes include various types of trans-acting ribozymes, for example, hammerhead ribozymes and hairpin ribozymes.

siRNA refers to double-stranded oligonucleotides capable of carrying out RNA interference (for example, Bass, 2001, Nature, 411, 428-429; Elbashir et al., 2001, Nature, 411, 494-498).

siRNA cleaves mRNA in a sequence-specific manner, and as a result inhibits translation of the mRNA into protein. siRNA includes double-stranded RNAs that are 20 to 25 base pairs long and comprise a sequence complementary to the target polynucleotide sequence. siRNAs of the present invention also include oligonucleotides comprising chemically modified nucleotides and non-nucleotides.

The present invention also relates to antibodies which bind to the above-described mutant polypeptide of the present invention, and antigen-binding fragments thereof

Antibodies of the present invention are not limited by their origin, form, function, etc. Antibodies of the present invention may be any antibodies, monoclonal or polyclonal antibodies. However, preferred antibodies of the present invention are monoclonal antibodies. Antibodies of the present invention may be those derived from any animal, such as human antibodies, mouse antibodies, and rat antibodies. Antibodies of the present invention may also be recombinant antibodies such as chimeric antibodies and humanized antibodies. Preferred antibodies of the present invention include chimeric antibodies, human antibodies, and humanized antibodies.

The humanized antibodies of the present invention can be prepared by methods known to those skilled in the art. The variable region of an antibody is typically composed of three complementarity-determining regions (CDRs) sandwiched by four frames (FRs). The CDRs practically determine the binding specificity of an antibody. The amino acid sequences of CDRs are highly diverse. On the other hand, amino acid sequences that constitute FRs often exhibit high homology among antibodies having different binding specificities. Therefore, it is said that in general the binding specificity of an antibody can be transplanted to a different antibody by grafting the CDRs.

Humanized antibodies are also referred to as reshaped human antibodies, and they are prepared by transferring the CDRs of an antibody derived from a non-human mammal such as a mouse, to the complementarity determining regions of a human antibody. General genetic recombination techniques for their preparation are also known (see European Patent Application Publication No. 125023 and WO 96/02576).

Specifically, for example, when the CDRs are derived from a mouse antibody, a DNA sequence is designed such that the CDRs of the mouse antibody are linked with the framework regions (FRs) of a human antibody, and it is synthesized by PCR using, as primers, several oligonucleotides that have portions overlapping the ends of both CDRs and FRs (see the method described in WO 98/13388). The resulting DNA is then ligated to a DNA encoding a human antibody constant region, inserted into an expression vector, and introduced into a host to produce the antibody (see European Patent Application Publication No. EP 239400 and International Patent Application Publication No. WO 96/02576).

Human antibody framework regions to be linked with CDRs are selected so that the complementarity determining regions form a favorable antigen-binding site. If needed, amino acids of the framework region in an antibody variable region may be substituted, deleted, added, and/or inserted so that the complementarity determining regions of the reshaped human antibody form a proper antigen-binding site. For example, mutations can be introduced into the amino acid sequence of the FR by applying the PCR method used to graft mouse CDRs to human FRs. Specifically, mutations can be introduced into a portion of the nucleotide sequences of primers that anneal to the FRs. The mutations are introduced into FRs synthesized using such primers. Mutant FR sequences having desired properties can be selected by assessing and determining the antigen-binding activity of amino acid-substituted mutant antibodies by the method described above and (Sato, K. et al., Cancer Res. (1993) 53, 851-856).

In general, constant regions from human antibodies are used for those of humanized antibodies.

There are no particular limitations to the human antibody constant regions to be used in the present invention; and for example, when using a heavy-chain constant region, it may be a human IgG1 constant region, human IgG2 constant region, human IgG3 constant region, human IgG4 constant region, or human IgM, IgA, IgE, or IgD constant region. Alternatively, when using a light-chain constant region, it may be a human lc chain constant region or human λ chain constant region. Furthermore, constant regions derived from a human antibody may have a naturally-occurring sequence or may be a constant region having a sequence with modification (substitution, deletion, addition, and/or insertion) of one or more amino acids in the naturally-occurring sequence.

Moreover, after a humanized antibody is prepared, amino acids in the variable region (for example, CDR and FR) and constant region of the humanized antibody may be deleted, added, inserted, and/or substituted with other amino acids. The humanized antibodies of the present invention also include such humanized antibodies with amino acid substitutions and such.

The origin of the CDRs of a humanized antibody is not particularly limited, and may be any animal. For example, it is possible to use sequences of mouse antibodies, rat antibodies, rabbit antibodies, camel antibodies, and such. CDR sequences of mouse antibodies are preferred.

When administered to humans for therapeutic purposes, humanized antibodies are useful because their immunogenicity in the human body is reduced. Chimeric antibodies comprise, for example, heavy and light chain constant regions of a human antibody, and heavy and light chain variable regions of an antibody of a non-human mammal, such as mouse. Chimeric antibodies can be prepared using known methods. For example, antibodies can be produced by cloning an antibody gene from hybridomas, inserting it into an appropriate vector, and introducing the construct into hosts (see, for example, Carl, A. K. Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). Specifically, cDNAs of the antibody variable regions (V regions) are synthesized from the hybridoma mRNAs using reverse transcriptase. Once DNAs encoding the V regions of an antibody of interest are obtained, they are linked with DNAs encoding the constant regions (C regions) of a desired human antibody. The resulting constructs are inserted into expression vectors. Alternatively, DNAs encoding the antibody V regions may be inserted into an expression vector comprising DNAs encoding the C regions of a human antibody. The DNAs are inserted into an expression vector so that they are expressed under the regulation of expression regulatory regions, for example, enhancers and promoters. In the next step, host cells can be transformed with the expression vector to allow expression of chimeric antibodies.

Human antibodies can be obtained using methods known to those skilled in the art. For example, desired human antibodies with antigen-binding activity can be obtained by sensitizing human lymphocytes with an antigen of interest or cells expressing an antigen of interest in vitro; and fusing the sensitized lymphocytes with human myeloma cells such as U266 (see Japanese Patent Application Kokoku Publication No. (JP-B) H01-59878 (examined, approved Japanese patent application published for opposition)). Alternatively, the desired human antibody can also be obtained by immunizing a transgenic animal having an entire repertoire of human antibody genes with a desired antigen (see International Patent Application Publication Nos. WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735).

Alternatively, B cells expressing antibodies that have antigen-binding activity are isolated from a pool of human lymphocytes by flow cytometry, cell array, or such. The antibody genes from selected B cells can be analyzed, and DNA sequences of the human antibodies that bind to the antigen can be determined (Jin, A. et al., Nature Medicine (2009) 15, 1088-92; Scheid, J. F. et al., Nature (2009) 458, 636-640; Wrammert, J. et al., Nature (2008) 453, 667-672; Tiller, T. et al., Journal of Immunological Methods (2008) 329, 112-124). When DNA sequences of the antigen-binding antibodies are revealed, human antibodies can be prepared by constructing appropriate expression vectors carrying the sequences. Such methods are known, and WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, and WO 95/15388 can be used as references.

Furthermore, techniques for obtaining human antibodies by panning with a human antibody phage library are known. For example, the variable region of a human antibody is expressed as a single chain antibody (scFv) on the phage surface using a phage display method, and phages that bind to the antigen can be selected. By analyzing the genes of selected phages, DNA sequences encoding the variable regions of human antibodies that bind to the antigen can be determined. If the DNA sequences of scFvs that bind to the antigen are identified, appropriate expression vectors comprising these sequences can be constructed to obtain human antibodies. Such methods are well known. Reference can be made to WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, WO 95/15388, and such.

The antibodies of the present invention include not only divalent antibodies as represented by IgG, but also monovalent antibodies, multivalent antibodies as represented by IgM. In addition, the antibodies of the present invention also include bispecific antibodies capable of binding to different antigens.

Antibodies of the present invention include not only whole antibody molecules but also any antigen-binding fragments such as low-molecular-weight antibodies.

Antibodies of the present invention also include modified antibodies that are linked to cytotoxic substances. Antibodies of the present invention also include those with altered sugar chains.

Low-molecular-weight antibodies (minibodies) included in antigen-binding fragments of the present invention are antibodies comprising an antibody fragment that lacks part of a whole antibody (for example, whole IgG, etc.). The minibodies are not particularly limited, as long as they have the activity to bind to a mutant polypeptide of the present invention.

Minibodies of the present invention are not particularly limited, as long as they comprise a portion of a whole antibody. It is however preferable that the minibodies comprise an antigen-binding domain. In general, the antigen-binding domain is antibody CDR, and is preferably six CDRs of an antibody. Thus, the preferred antigen-binding domains include, for example, six CDRs of an antibody and antibody variable regions (heavy chain and/or light chain variable regions).

The minibodies of the present invention preferably have a smaller molecular weight than whole antibodies. However, the minibodies may form multimers, for example, dimers, trimers, or tetramers, and thus their molecular weights can be greater than those of whole antibodies.

Other specific examples of the antigen-binding molecule fragments include, for example, Fab, Fab′, F(ab′)2, and Fv. Meanwhile, specific examples of low-molecular-weight antibodies include, for example, Fab, Fab′, F(ab′)2, Fv, scFv (single chain Fv), diabodies, and sc(Fv)2 (single chain (Fv)2). Multimers (for example, dimers, trimers, tetramers, and polymers) of these antibodies are also included in the low-molecular-weight antibodies of the present invention.

Antigen-binding fragments can be obtained, for example, by treating antibodies with enzymes to produce antibody fragments. Enzymes known to generate antibody fragments include, for example, papain, pepsin, and plasmin. Alternatively, a gene encoding such an antibody fragment can be constructed, introduced into an expression vector, and expressed in appropriate host cells (see, for example, Co, M. S. et al., J. Immunol. (1994) 152, 2968-2976; Better, M. & Horwitz, A. H. Methods in Enzymology (1989) 178, 476-496; Plueckthun, A. & Skerra, A. Methods in Enzymology (1989) 178, 476-496; Lamoyi, E., Methods in Enzymology (1989) 121, 652-663; Rousseaux, J. et al., Methods in Enzymology (1989) 121, 663-669; Bird, R. E. et al., TIBTECH (1991) 9, 132-137).

Digestive enzymes cleave at a specific site in an antibody fragment, yielding antibody fragments of specific structures shown below. Genetic engineering techniques can be applied to such enzymatically-obtained antibody fragments to delete an arbitrary portion of the antibody.

Antibody fragments obtained by using the above-described digestive enzymes are as follows:

Papain digestion: F(ab)2 or Fab Pepsin digestion: F(ab′)2 or Fab′ Plasmin digestion: Facb

The minibodies of the present invention include antibody fragments lacking an arbitrary region, as long as they have the activity to bind to a mutant polypeptide of the present invention.

“Diabody” refers to a bivalent antibody fragment constructed by gene fusion (Holliger P et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993); EP 404,097; WO 93/11161, etc.). Diabodies are dimers composed of two polypeptide chains. In each of the polypeptide chains forming a dimer, a VL and a VH are usually linked by a linker in the same chain. In general, the linker in a diabody is short enough such that the VL and VH cannot bind to each other. Specifically, the number of amino acid residues constituting the linker is, for example, about five residues. Thus, the VL and VH encoded on the same polypeptide cannot form a single-chain variable region fragment, and will form a dimer with another single-chain variable region fragment. As a result, the diabody has two antigen binding sites.

scFv antibodies are single-chain polypeptides produced by linking a heavy chain variable region ([VH]) to a light chain variable region ([VL]) via a linker or such (Huston, J. S. et al., Proc. Natl. Acad. Sci. U.S.A. (1988) 85, 5879-5883; Plickthun “The Pharmacology of Monoclonal Antibodies” Vol. 113, eds., Resenburg and Moore, Springer Verlag, New York, pp. 269-315, (1994)). The H-chain V region and L-chain V region of scFv may be derived from any antibody described herein. The peptide linker for linking the V regions is not particularly limited. For example, an arbitrary single-chain peptide containing about three to 25 residues can be used as a linker. Specifically, it is possible to use the peptide linkers or such described below.

The V regions of both chains can be linked, for example, by PCR as described above. To link the V regions by PCR, first, a DNA from the DNAs below that encodes a complete or desired partial amino acid sequence is used as a template:

DNA sequence encoding an H chain or H-chain V region of an antibody, and DNA sequence encoding an L chain or L-chain V region of an antibody.

DNAs encoding the H-chain and L-chain V regions are amplified by PCR using a pair of primers having sequences corresponding to sequences at both ends of the DNA to be amplified. Then, a DNA encoding the peptide linker portion is prepared. The peptide linker-encoding DNA can also be synthesized by PCR. Here, nucleotide sequences that can be ligated to the amplification products of V regions synthesized separately are added to the 5′ end of the primers to be used. Then, PCR is carried out using each DNA of the [H chain V region DNA]-[peptide linker DNA]-[L chain V region DNA], and assembly PCR primers.

The assembly PCR primers are composed of a combination of a primer that anneals to the 5′ end of the [H chain V region DNA] and a primer that anneals to the 3′ end of the [L chain V region DNA]. In other words, the assembly PCR primers are a set of primers that can be used to amplify DNA encoding the full-length sequence of an scFv to be synthesized. Meanwhile, nucleotide sequences that can be ligated to the V-region DNAs have been added to the [peptide linker DNA]. Thus, these DNAs are linked together, and then the whole scFv is ultimately generated as an amplification product by the assembly PCR primers. Once the scFv-encoding DNAs are generated, expression vectors carrying these DNAs and recombinant cells transformed with these expression vectors can be obtained by conventional methods. Furthermore, the scFv can be obtained by culturing the resulting recombinant cells to express the scFv-encoding DNAs.

The order of the heavy chain and light chain variable regions to be linked together is not particularly limited, and they may be arranged in any order. Examples of the arrangement are listed below.

[VH] linker [VL] [VL] linker [VH]

sc(Fv)2 is a single-chain low-molecular-weight antibody produced by linking two VHs and two VLs using linkers and such (Hudson et al., J Immunol. Methods 1999; 231: 177-189). For example, sc(Fv)2 can be produced by linking scFvs via a linker.

Antibodies in which two VHs and two VLs are arranged in the order of VH, VL, VH, and VL ([VH] linker [VL] linker [VH] linker [VL]) from the N terminus of the single-chain polypeptide are preferred. However, the order of the two VHs and two VLs is not limited to the above arrangement, and they may be arranged in any order. Examples of the arrangement are listed below:

[VL] linker [VH] linker [VH] linker [VL] [VH] linker [VL] linker [VL] linker [VH] [VH] linker [VH] linker [VL] linker [VL] [VL] linker [VL] linker [VH] linker [VH] [VL] linker [VH] linker [VL] linker [VH]

The amino acid sequence of the heavy chain variable region or light chain variable region in a low-molecular-weight antibody may contain a substitution, deletion, addition, and/or insertion. Furthermore, the heavy chain variable region and light chain variable region may also lack some portions or be added with other polypeptides, as long as they have antigen binding ability when linked together. Alternatively, the variable regions may be chimerized or humanized.

In the present invention, linkers which bind the variable regions of the antibody include arbitrary peptide linkers that can be introduced using genetic engineering, or synthetic linkers such as those disclosed in Protein Engineering, 9(3), 299-305, 1996.

The preferred linkers in the present invention are peptide linkers. The length of the peptide linkers is not particularly limited, and those skilled in the art can appropriately select the length depending on the purpose. A typical length is one to 100 amino acids, preferably 3 to 50 amino acids, more preferably 5 to 30 amino acids, and particularly preferably 12 to 18 amino acids (for example, 15 amino acids).

Amino acid sequences of such peptide linkers include, for example:

Ser; Gly•Ser; Gly•Gly•Ser; Ser•Gly•Gly; (SEQ ID NO: 13) Gly•Gly•Gly•Ser; (SEQ ID NO: 14)  Ser•Gly•Gly•Gly; (SEQ ID NO: 15)  Gly•Gly•Gly•Gly•Ser; (SEQ ID NO: 16)  Ser•Gly•Gly•Gly•Gly; (SEQ ID NO: 17)  Gly•Gly•Gly•Gly•Gly•Ser; (SEQ ID NO: 18)  Ser•Gly•Gly•Gly•Gly•Gly; (SEQ ID NO: 19)  Gly•Gly•Gly•Gly•Gly•Gly•Ser; (SEQ ID NO: 20)  Ser•Gly•Gly•Gly•Gly•Gly•Gly; (Gly•Gly•Gly•Gly•Ser (SEQ ID NO: 15))n; and (Ser•Gly•Gly•Gly•Gly (SEQ ID NO: 16))n, where n is an integer of 1 or larger.

The amino acid sequence of a peptide linker can be appropriately selected by those skilled in the art according to the purpose. For example, the above-mentioned “n”, which determines the length of the peptide linker, is usually 1 to 5, preferably 1 to 3, and more preferably 1 or 2.

Synthetic linkers (chemical crosslinking agents) include crosslinking agents that are routinely used to crosslink peptides, for example, N-hydroxy succinimide (NHS), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl) suberate (BS3), dithiobis(succinimidyl propionate) (DSP), dithiobis(sulfosuccinimidyl propionate) (DTSSP), ethylene glycol bis(succinimidyl succinate) (EGS), ethylene glycol bis(sulfosuccinimidyl succinate) (sulfo-EGS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo-DST), bis[2-(succinimidoxycarbonyloxy)ethyl] sulfone (BSOCOES), and bis[2-(sulfosuccinimidoxycarbonyloxy)ethyl] sulfone (sulfo-BSOCOES). These crosslinking agents are commercially available.

When four antibody variable regions are linked, three linkers are usually required. Such multiple linkers may be the same or different.

The antibodies of the present invention include antibodies in which one or more amino acid residues have been added to the amino acid sequence of an antibody of the present invention. Further, fusion proteins which result from a fusion between one of the above antibodies and a second peptide or protein is included in the present invention. The fusion proteins can be prepared by ligating a polynucleotide encoding an antibody of the present invention with a polynucleotide encoding a second peptide or polypeptide in frame, inserting this into an expression vector, and expressing the fusion construct in a host. Some techniques known to those skilled in the art are available for this purpose. The partner peptide or polypeptide to be fused with an antibody of the present invention may be a known peptide, for example, FLAG (Hopp, T. P. et al., BioTechnology 6, 1204-1210 (1988)), 6×His consisting of six His (histidine) residues, 10×His, influenza hemagglutinin (HA), human c-myc fragment, VSV-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40 T antigen fragment, lck tag, α-tubulin fragment, B-tag, Protein C fragment, Stag, StrepTag, HaloTag. Other partner polypeptides to be fused with the antibodies of the present invention include, for example, GST (glutathione-S-transferase), HA (influenza hemagglutinin), immunoglobulin constant region, β-galactosidase, and MBP (maltose-binding protein). A polynucleotide encoding one of these commercially available peptides or polypeptides can be fused with a polynucleotide encoding an antibody of the present invention. The fusion polypeptide can be prepared by expressing the fusion construct.

Furthermore, the antibodies of the present invention may be conjugated antibodies which are linked to any of various molecules including polymeric substances such as polyethylene glycol (PEG) and hyaluronic acid, radioactive substances, fluorescent substances, luminescent substances, enzymes, and toxins. Such conjugated antibodies can be obtained by chemically modifying the obtained antibodies. Methods for modifying antibodies have been established in this field (for example, U.S. Pat. Nos. 5,057,313 and 5,156,840). The “antibodies” of the present invention also include such conjugated antibodies.

Furthermore, the antibodies used in the present invention may be bispecific antibodies. The bispecific antibody refers to an antibody that has variable regions recognizing different epitopes in the same antibody molecule. In the present invention, the bispecific antibodies may recognize different epitopes on the mutant polypeptide molecule of the present invention, or recognize the mutant polypeptide of the present invention with one antigen-binding site and a different substance with the other antigen-binding site.

Methods for producing bispecific antibodies are known. Bispecific antibodies can be prepared, for example, by linking two antibodies that recognize different antigens. Antibodies to be linked together may be half molecules each of which contains an H chain and an L chain, or quarter molecules that consist of only one H chain. Alternatively, hybridomas producing different monoclonal antibodies can be fused to produce a bispecific antibody-producing fused cell. Furthermore, bispecific antibodies can be produced by genetic engineering techniques.

The antibodies of the present invention may differ in amino acid sequence, molecular weight, isoelectric point, presence/absence of sugar chains, and conformation depending on the cell or host producing the antibody or the purification method as described below. However, a resulting antibody is included in the present invention, as long as it is functionally equivalent to an antibody of the present invention. For example, when an antibody of the present invention is expressed in prokaryotic cells, for example E. coli, a methionine residue is added to the N terminus of the original antibody amino acid sequence. Such antibodies are included in the present invention.

Antibodies of the present invention may be antibodies with altered sugar chains. Methods for modifying antibody sugar chains are known to those skilled in the art, and include, for example, methods for improving ADCC by modifying antibody glycosylation, methods for adjusting ADCC by the presence or absence of fucose in antibody sugar chains, methods for preparing antibodies having sugar chains that do not contain α-1,6 core fucose by producing antibodies in YB2/0 cells, and methods for adding sugar chains having bisecting GlcNAc (WO 99/54342; WO 00/61739; WO 02/31140; WO 02/79255, etc.).

Antibodies of the present invention can be produced by known methods using as an immunogen a mutant polypeptide of the present invention (derived from mammals such as humans and mice) or a fragment thereof. Specifically, non-human mammals are immunized by a known immunization method, using as a sensitizing antigen a desired antigen or cells expressing a desired antigen. Immune cells prepared from the immunized animals are fused with known parental cells by a general cell fusion method. The resulting monoclonal antibody-producing cells (hybridomas) are sorted by general screening methods, and monoclonal antibodies are prepared by culturing the cells.

Non-human mammals to be immunized include, for example, animals such as mice, rats, rabbits, sheep, monkeys, goats, donkeys, cows, horses, and pigs. The antigen can be prepared using a polynucleotide encoding the mutant polypeptide of the present invention according to known methods, for example, by methods using baculovirus (for example, WO 98/46777) or such.

Hybridomas can be prepared, for example, according to the method of Milstein et al. (Kohler, G. and Milstein, C., Methods Enzymol. (1981) 73: 3-46) or such. When the immunogenicity of an antigen is low, immunization may be performed after linking the antigen with a macromolecule having immunogenicity, such as albumin.

In an embodiment, antibodies that bind to the mutant polypeptides of the present invention include monoclonal antibodies that bind to the mutant polypeptides of the present invention. Immunogens for preparing monoclonal antibodies having binding activity to a mutant polypeptide of the present invention are not particularly limited, as long as antibodies having binding activity to the mutant polypeptide of the present invention can be prepared.

Meanwhile, the activity of an antibody to bind to a mutant polypeptide of the present invention can be assayed by methods known to those skilled in the art.

Meanwhile, monoclonal antibodies can also be obtained by DNA immunization. DNA immunization is a method in which a vector DNA constructed such that an antigen protein-encoding gene can be expressed in an animal to be immunized is administered to the animal, and the immunogen is expressed within the body of the animal to provide immunostimulation. As compared to common immunization methods based on the administration of protein antigens, DNA immunization is expected to be advantageous in that:

it enables immunostimulation while retaining the structure of a membrane protein; and the immunogen does not need to be purified.

In order to obtain monoclonal antibodies by DNA immunization, first, a polynucleotide encoding a mutant polypeptide of the present invention is administered to an animal to be immunized. The polynucleotide encoding a mutant polypeptide of the present invention can be synthesized according to an above-described method by known techniques such as PCR. The resulting DNA (polynucleotide) is inserted into an appropriate expression vector and then administered to an animal to be immunized. The expression vector includes any vectors described above (for example, commercially available expression vectors such as pcDNA3.1). Vectors can be administered to a living body by commonly used methods. For example, DNA immunization can be performed, for example, by using a gene gun to inject gold particles immobilized with an expression vector into cells. A preferred method for obtaining monoclonal antibodies is to perform booster immunization with cells expressing the mutant polypeptide of the present invention after DNA immunization.

Once the mammal is immunized as described above and the serum level of a desired antibody is confirmed to be increased, immune cells are collected from the mammal and subjected to cell fusion. Preferred immune cells are spleen cells in particular.

Mammalian myeloma cells are used for fusion with the above immune cells. It is preferred that myeloma cells have appropriate selection markers for screening. The selection marker refers to a phenotype that allows (or does not allow) survival under particular culture conditions. Known selection markers include hypoxanthine-guanine-phosphoribosyltransferase deficiency (hereinafter abbreviated as “HGPRT deficiency”) and thymidine kinase deficiency (hereinafter abbreviated as “TK deficiency”). HGPRT- or TK-deficient cells exhibit hypoxanthine-aminopterin-thymidine sensitivity (hereinafter abbreviated as “HAT sensitivity”). In HAT selection medium, HAT-sensitive cells cannot synthesize DNA and thus will die. However, when fused with normal cells, they can continue to synthesize DNA via the salvage pathway of the normal cells and thus can grow even in HAT selection medium.

HGPRT- or TK-deficient cells can be selected using a medium containing 6-thioguanine, 8-azaguanine (hereinafter abbreviated as “8AG”), or 5′-bromodeoxyuridine. While normal cells are killed due to incorporation of these pyrimidine analogs into DNA, cells lacking these enzymes can survive in the selection medium because they cannot incorporate these pyrimidine analogs. Another selection marker called G418 resistance confers resistance to 2-deoxystreptamine antibiotics (gentamicin analogs) due to the neomycin resistance gene. Various myeloma cells suitable for cell fusion are known.

Cell fusion between immune cells and myeloma cells can be essentially carried out according to known methods, for example, the method by Kohler and Milstein et al. (Kohler. G. and Milstein, C., Methods Enzymol. (1981) 73, 3-46).

More specifically, cell fusion can be carried out, for example, in a common culture medium in the presence of a cell fusion-promoting agent. The fusion-promoting agent includes, for example, polyethylene glycol (PEG) and Sendai virus (HVJ). If required, an auxiliary agent such as dimethyl sulfoxide may also be added to improve fusion efficiency.

The immune cells and myeloma cells may be used at an arbitrarily determined ratio. For example, the ratio of immune cells to myeloma cells is preferably from 1 to 10. Culture media to be used for cell fusion include, for example, media that are suitable for the cell growth of myeloma cell line, such as RPMI1640 and MEM, and other common culture media used for this type of cell culture. In addition, the culture media may also be supplemented with serum supplement such as fetal calf serum (FCS).

Predetermined amounts of immune cells and myeloma cells are mixed well in the culture medium, and then mixed with a PEG solution pre-heated to about 37° C. to produce fused cells (hybridomas). In the cell fusion method, for example, PEG with mean molecular weight of about 1,000-6,000 can be added to the cells typically at a concentration of 30% to 60% (w/v). Then, successive addition of the appropriate culture medium listed above and removal of supernatant by centrifugation are repeated to eliminate the cell fusion agent and such, which are unfavorable to the growth of hybridomas.

The resulting hybridomas can be screened using a selection medium according to the selection marker possessed by myeloma cells used in the cell fusion. For example, HGPRT- or TK-deficient cells can be screened by culturing them in a HAT medium (a medium containing hypoxanthine, aminopterin, and thymidine). Specifically, when HAT-sensitive myeloma cells are used in cell fusion, cells successfully fused with normal cells can be selectively grown in the HAT medium. The cell culture using the above HAT medium is continued for a sufficient period of time to allow all cells except the desired hybridomas (non-fused cells) to die. Specifically, in general, the desired hybridomas can be selected by culturing the cells for several days to several weeks. Then, screening and single cloning of hybridomas that produce an antibody of interest can be carried out by performing ordinary limiting dilution methods.

Screening and single cloning of an antibody of interest can be suitably carried out by known screening methods based on antigen-antibody reaction. For example, an antigen is bound to a carrier such as beads made of polystyrene or such and commercially available 96-well microtiter plates, and then reacted with the culture supernatant of hybridoma. Next, the carrier is washed and then reacted with an enzyme-labeled secondary antibody or such. When the culture supernatant contains an antibody of interest reactive to the sensitizing antigen, the secondary antibody binds to the carrier via this antibody. Finally, the secondary antibody bound to the carrier is detected to determine whether the culture supernatant contains the antibody of interest. Hybridomas producing a desired antibody capable of binding to the antigen can be cloned by the limiting dilution method or such.

In addition to the above-described method for preparing hybridomas through immunization of a nonhuman animal with an antigen, antibodies of interest can also be obtained by sensitizing human lymphocytes with an antigen. Specifically, first, human lymphocytes are sensitized with the mutant polypeptide of the present invention in vitro. Then, the sensitized lymphocytes are fused with an appropriate fusion partner. For example, human-derived myeloma cells with the ability to divide permanently can be used as the fusion partner (see JP-B (Kokoku) H01-59878). Antibodies obtained by this method are human antibodies having an activity of binding to the mutant polypeptide of the present invention.

The nucleotide sequence encoding an antibody that binds to the mutant polypeptide of the present invention obtained by the above-described method or such, and its amino acid sequence can be obtained by methods known to those skilled in the art.

Based on the obtained sequence of the antibody that binds to the mutant polypeptide of the present invention, the antibody that binds to the mutant polypeptide of the present invention can be prepared by genetic recombination techniques known to those skilled in the art. Specifically, a polynucleotide encoding an antibody can be constructed based on the sequence of the antibody that recognizes the mutant polypeptides of the present invention, inserted into an expression vector, and then expressed in appropriate host cells (see for example, Co, M. S. et al., J. Immunol. (1994) 152, 2968-2976; Better, M. and Horwitz, A. H., Methods Enzymol. (1989) 178, 476-496; Pluckthun, A. and Skerra, A., Methods Enzymol. (1989) 178, 497-515; Lamoyi, E., Methods Enzymol. (1986) 121, 652-663; Rousseaux, J. et al., Methods Enzymol. (1986) 121, 663-669; Bird, R. E. and Walker, B. W., Trends Biotechnol. (1991) 9, 132-137).

The vectors include M13 vectors, pUC vectors, pBR322, pBluescript, and pCR-Script. Alternatively, when aiming to subclone and excise cDNA, the vectors include, for example, pGEM-T, pDIRECT, and pT7, in addition to the vectors described above. Expression vectors are particularly useful when using vectors for producing the antibodies of the present invention. For example, when aiming for expression in E. coli such as JM109, DH5α, HB101, and XL1-Blue, the expression vectors not only have the above-described characteristics that allow vector amplification in E. coli, but must also carry a promoter that allows efficient expression in E. coli, for example, lacZ promoter (Ward et al., Nature (1989) 341, 544-546; FASEB J. (1992) 6, 2422-2427), araB promoter (Better et al., Science (1988) 240, 1041-1043), T7 promoter or such. Such vectors include pGEX-5X-1 (Pharmacia), “QIAexpress system” (Qiagen), pEGFP, or pET (in this case, the host is preferably BL21 that expresses T7 RNA polymerase) in addition to the vectors described above.

The vectors may contain signal sequences for antibody secretion. As a signal sequence for antibody secretion, a pelB signal sequence (Lei, S. P. et al J. Bacteriol. (1987) 169, 4379) may be used when a protein is secreted into the E. coli periplasm. The vector can be introduced into host cells by calcium chloride or electroporation methods, for example.

In addition to vectors for E. coli, the vectors for producing the antibodies of the present invention include mammalian expression vectors (for example, pcDNA3 (Invitrogen), pEF-BOS (Nucleic Acids. Res. 1990, 18(17), p5322), pEF, and pCDM8), insect cell-derived expression vectors (for example, the “Bac-to-BAC baculovirus expression system” (Gibco-BRL) and pBacPAK8), plant-derived expression vectors (for example, pMH1 and pMH2), animal virus-derived expression vectors (for example, pHSV, pMV, and pAdexLcw), retroviral expression vectors (for example, pZlPneo), yeast expression vectors (for example, “Pichia Expression Kit” (Invitrogen), pNV11, and SP-Q01), and Bacillus subtilis expression vectors (for example, pPL608 and pKTH50), for example.

When aiming for expression in animal cells such as CHO, COS, and NIH3T3 cells, the vectors must have a promoter essential for expression in cells, for example, SV40 promoter (Mulligan et al., Nature (1979) 277, 108), MMLV-LTR promoter, EFla promoter (Mizushima et al., Nucleic Acids Res. (1990) 18, 5322), and CMV promoter, and more preferably they have a gene for selecting transformed cells (for example, a drug resistance gene that allows evaluation using an agent (neomycin, G418, or such)). Vectors with such characteristics include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13, for example.

In addition, the following method can be used for stable gene expression and gene amplification in cells: CHO cells deficient in a nucleic acid synthesis pathway are introduced with a vector (for example, pSV2-dhfr (“Molecular Cloning 2^(nd) edition”, Cold Spring Harbor Laboratory Press, 1989)) that carries a DHFR gene which compensates for the deficiency, and the vector is amplified using methotrexate (MTX). Alternatively, the following method can be used for transient gene expression: COS cells with a gene expressing SV40 T antigen on their chromosome are transformed with a vector (pcD and such) with an SV40 replication origin. Replication origins derived from polyoma virus, adenovirus, bovine papilloma virus (BPV), and such can also be used. To amplify gene copy number in host cells, the expression vectors may further carry selection markers such as aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, E. coli xanthine-guanine phosphoribosyltransferase (Ecogpt) gene, and dihydrofolate reductase (dhfr) gene.

The antibodies of the present invention obtained by the methods described above can be isolated from inside host cells or from outside the cells (the medium, or such), and purified to homogeneity. The antibodies can be isolated and purified by methods routinely used for isolating and purifying antibodies, and the type of method is not limited. For example, the antibodies can be isolated and purified by appropriately selecting and combining column chromatography, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectrofocusing, dialysis, recrystallization, and such.

The chromatographies include, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). The chromatographic methods described above can be conducted using liquid chromatography, for example, HPLC and FPLC. Columns that can be used for affinity chromatography include protein A columns and protein G columns. Columns using protein A include, for example, Hyper D, POROS, and Sepharose FF (GE Amersham Biosciences). The present invention includes antibodies that are highly purified using these purification methods.

The binding activity to the mutant polypeptide of the present invention of the obtained antibodies can be determined by methods known to those skilled in the art. Methods for determining the antigen-binding activity of an antibody include, for example, ELISA (enzyme-linked immunosorbent assay), EIA (enzyme immunoassay), RIA (radioimmunoassay), and fluorescent antibody method. For example, when enzyme immunoassay is used, antibody-containing samples, such as purified antibodies and culture supernatants of antibody-producing cells, are added to antigen-coated plates. A secondary antibody labeled with an enzyme, such as alkaline phosphatase, is added and the plates are incubated. After washing, an enzyme substrate, such as p-nitrophenyl phosphate, is added, and the absorbance is measured to evaluate the antigen-binding activity.

In the present invention, “cancer” generally refers to malignant neoplasm which may be metastatic or non-metastatic. For instance, non-limiting examples of cancer that develops from epithelial tissues such as gastrointestinal tract and skin include brain tumor, skin cancer, head and neck cancer, esophageal cancer, lung cancer, gastric cancer, duodenal cancer, breast cancer, prostate cancer, cervical cancer, cancer of uterine body, pancreatic cancer, liver cancer, colorectal cancer, colon cancer, bladder cancer, and ovarian cancer. Meanwhile, non-limiting examples of sarcoma that develops from non-epithelial tissues (stroma) such as muscles include osteosarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, liposarcoma, and angiosarcoma. Furthermore, non-limiting examples of hematological cancer derived from hematopoietic organs include malignant lymphoma including Hodgkin's lymphoma and non-Hodgkin's lymphoma, leukemia including acute myelocytic leukemia, chronic myelocytic leukemia, acute lymphatic leukemia, and chronic lymphatic leukemia, and multiple myeloma.

In the present invention, cancer includes any newly developed pathological tissue tumor (neoplasm). In the present invention, neoplasm leads to tumor formation which is characterized by partial neovascularization. Neoplasm can be benign, for example, angioma, glioma, and teratoma, or malignant, for example, cancer, sarcoma, glial tumor, astrocytoma, neuroblastoma, and retinoblastoma.

In the present invention, preferred examples of cancer include bladder cancer, brain tumor, head and neck squamous cell carcinoma, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, and liver cancer.

In the present invention, “cancer tissue” refers to a tissue containing at least one cancer cell. For example, as cancer tissues contain cancer cells and blood vessels, cancer tissue refers to all cell types that contribute to the formation of tumor mass containing cancer cells and endothelial cells. Herein, tumor mass refers to foci of tumor tissue. The term “tumor” is generally used to refer to benign or malignant neoplasm.

The present invention relates to pharmaceutical compositions comprising an above-described antibody or antigen-binding fragment thereof, oligonucleotides, or a compound of the present invention.

In the present invention, the pharmaceutical composition generally refers to a pharmaceutical agent for treating, preventing, or examining/diagnosing diseases.

The pharmaceutical compositions of the present invention can be formulated by methods known to those skilled in the art. For example, they can be used parenterally, in an injectable form of sterile solutions or suspensions including water or other pharmaceutically acceptable liquid. For example, such compositions may be formulated by mixing in a unit dose form required by the generally approved pharmaceutical manufacturing practice, by appropriately combining with pharmacologically acceptable carriers or media, specifically sterile water, physiological saline, vegetable oil, emulsifier, suspension, surfactant, stabilizer, flavoring agent, excipient, vehicle, preservative, binder, or such. The amount of active ingredient in such formulations is adjusted so that an appropriate amount can be obtained within a specified range.

Sterile compositions for injection can be formulated according to general formulation practice using vehicles such as distilled water for injection. Aqueous solutions for injection include, for example, physiological saline, and isotonic solutions containing glucose or other adjuvants (e.g., D-sorbitol, D-mannnose, D-mannitol, and sodium chloride). These can be used in combination with appropriate solubilizers, for example, alcohol (ethanol, etc.), polyalcohol (propylene glycol, polyethylene glycol, etc.), and non-ionic detergents (Polysorbate 80™, HCO-50, etc.).

Oils include sesame oil and soybean oils. Benzyl benzoate and/or benzyl alcohol can be used in combination as solubilizers. It is also possible to combine buffers (for example, phosphate buffer and sodium acetate buffer), soothing agents (for example, procaine hydrochloride), stabilizers (for example, benzyl alcohol and phenol), and/or antioxidants. Appropriate ampules are filled with the prepared injections.

The pharmaceutical compositions of the present invention are preferably administered parenterally. For example, compositions are administered in an injectable form, or in a form for transnasal administration, transpulmonary administration, or transdermal administration. For example, they can be administered systemically or locally by intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, or such.

Administration methods can be appropriately selected in consideration of the patient's age and symptoms. The dose of a pharmaceutical composition containing an antigen-binding molecule may be, for example, 0.0001 mg to 1,000 mg/kg for each administration. Alternatively, the dose may be, for example, 0.001 to 100,000 mg per patient. However, the present invention is not limited by the numeric values described above. The dosage and administration method vary according to the patient's weight, age, symptoms, and such. Those skilled in the art can set an appropriate dosage and administration method in consideration of the factors described above.

Amino acids in the amino acid sequences described herein may be modified after translation (for example, modification of N-terminal glutamine into pyroglutamic acid by pyroglutamylation is well known to those skilled in the art). As a matter of course, such posttranslationally modified amino acids are also included in the amino acid sequences of the present invention.

The present invention also relates to methods for detecting an above-described mutant polypeptide of the present invention or a polynucleotide encoding the mutant polypeptide in samples from subjects (including cancer patients and healthy persons).

The presence or absence of a mutant polypeptide of the present invention in a sample from a subject can be tested and determined, for example, using antigen-antibody reaction which is performed by contacting an above-described antibody or antigen-binding fragment thereof that binds to a mutant polypeptide of the present invention with a sample (tumor tissue, normal tissue, and various body fluid specimens containing cancer or normal cells (blood, serum, urine, saliva, ascites, pleural effusion, etc.)) collected from a subject (cancer patient, person who may be affected with cancer, person with the risk of getting cancer, or healthy person; however, it is not limited to human).

The antigen (i.e., a mutant polypeptide of the present invention) in an antigen-antibody reaction can be detected, for example, by using conventional immunoassay.

In the present invention, immunoassay refers to a method for detecting a mutant polypeptide of the present invention in a sample (tumor tissue, normal tissue, and various body fluid specimens containing cancer or normal cells (blood, serum, urine, saliva, ascites, pleural effusion, etc.)) based on the reaction mechanism between an antigen (i.e., a mutant polypeptide of the present invention) and an antibody that binds to the antigen or antigen-binding fragment thereof. Any immunoassay is included in the present invention as long as it is a method that can detect the fusion polypeptides of the present invention.

For immunoassay in the present invention, for example, the principles of various methods such as those described in “Kouso Men-eki Sokutei Hou (Enzyme immunoassay)” (3rd Ed., eds., Eiji Ishikawa et al., Igakushoin, 1987) can be applied. Specifically, these various methods can be carried out using one or more antibodies that bind to an antigen of interest to capture (trap) the antigen to be detected in a sample.

Applicable principles preferably include, for example, single antibody solid phase methods, double antibody liquid phase methods, double antibody solid phase methods, sandwich methods, and one-pot methods such as described in JP-B (Kokoku) H02-39747. Meanwhile, assays based on antigen-antibody reaction also include enzyme multiplied immunoassay technique (EMIT), enzyme channeling immunoassay, enzyme modulator mediated enzyme immunoassay (EMMIA), enzyme inhibitor immunoassay, immunoenzymometric assay, enzyme enhanced immunoassay, and proximal linkage immunoassay.

In the present invention, it is possible to select and use any appropriate immunoassay principle such as those described above depending on the objective of the test.

The immunoassays of the present invention also include sandwich methods using a biotin- or enzyme-labeled antibody, and multi-well microtiter plates having a number of wells including 96-well microplate, as well as one-pot methods using beads and antibodies labeled with biotin or enzyme such as peroxidase.

As described above, antibodies that bind to a mutant polypeptide of the present invention or antigen-binding fragments thereof, which are used in immunoassays of the present invention, may be labeled with a labeling substance that can provide a detectable signal by itself or upon reaction with other substances.

Such labeling substances include, for example, enzymes, fluorescent substances, chemiluminescent substances, biotin, avidin, and radioisotopes. More specifically, the substances include enzymes such as peroxidase (e.g., horseradish peroxidase), alkaline phosphatase, β-D-galactosidase, glucose oxidase, glucose-6-phosphate dehydrogenase, alcohol dehydrogenase, malate dehydrogenase, penicillinase, catalase, apoglucoseoxidase, urease, luciferase, and acetylcholinesterase; fluorescent substances such as fluorescein isothiocyanate, phycobiliprotein, rare earth metal chelates, dansyl chloride, and tetramethylrhodamine isothiocyanate; radioisotopes such as ³H, ¹⁴C, ¹²⁵I, and ¹³¹I; biotin; avidin; and chemiluminescent substances.

Such radioisotopes and fluorescent substances can provide a detectable signal by themselves.

Meanwhile, enzymes, chemiluminescent substances, biotin, and avidin cannot provide any detectable signal by themselves, but provide a detectable signal when reacting with one or more different substances.

For example, when an enzyme is used, at least a substrate is necessary. Various substrates are used according to the type of enzymatic activity assay method (colorimetric assay, fluorescent assay, bioluminescence assay, chemiluminescent assay, etc.). For example, hydrogen peroxide is used as a substrate for peroxidase. Meanwhile, biotin is generally reacted with at least avidin or enzyme-modified avidin, but substrates are not limited thereto. If needed, it is also possible to use various chromogenic substances according to the substrates.

The presence or absence of a polynucleotide encoding a mutant polypeptide of the present invention in a sample from a subject can be tested and determined, for example, according to routine methods using various oligonucleotides (a pair of oligonucleotide primers, oligonucleotide probes, etc.) of the present invention described above, and mRNA, cDNA prepared using mRNA as a template, genomic DNA, or such in a sample (tumor tissue, normal tissue, and various body fluid specimens containing cancer or normal cells (blood, serum, urine, saliva, ascites, pleural effusion, etc.)) collected from a subject (cancer patient, person who may be affected with cancer, person with the risk of getting cancer, or healthy person; however, it is not limited to human) by using various gene analysis methods. Such gene analysis methods include, for example, Northern blotting, polymerase chain reaction (PCR), Southern blotting, ligase chain reaction (LCR), strand displacement amplification (SDA), nucleic acid sequence-based amplification (NASBA), isothermal and chimeric primer-initiated amplification of nucleic acids (ICAN), loop-mediated isothermal amplification (LAMP), TMA method (Gen-Probe's TMA system), microarray, and next-generation sequencing method.

These assays utilize hybridization of oligonucleotides of the present invention to a polynucleotide encoding a mutant polypeptide of the present invention derived from a sample. Desired stringent conditions for such hybridization include, for example, the conditions of 6 M urea, 0.4% SDS, 0.5×SSC, and 37° C.; and hybridization conditions of equivalent stringency. Depending on the objective, it is possible to use more stringent conditions, for example, 6 M urea, 0.4% SDS, and 0.1×SSC, and 42° C.

The present invention also relates to kits for detecting an above-described mutant polypeptide of the present invention or a polynucleotide encoding the mutant polypeptide in samples from subjects described above (including cancer patients and healthy persons).

Specifically, detection kits of the present invention may contain an above-described antibody or antigen-binding fragment thereof that binds to a mutant polypeptide of the present invention (including antibodies or antigen-binding fragments thereof labeled with above-described various labeling substances). Depending on the objective of each immunoassay described above, the kits may also contain various detection reagents (enzymes, substrates, etc.) and instruction manuals.

Specifically, detection kits of the present invention may contain various oligonucleotides of the present invention described above (a pair of oligonucleotide primers, oligonucleotide probes, etc.) that hybridize to mRNA derived from a polynucleotide encoding an above-described mutant polypeptide of the present invention, cDNA prepared using the mRNA as template, or genomic DNA. According to the objective of each gene analysis, the kits may also contain various reagents (enzymes, other oligonucleotides, nucleic acid, reaction buffer, etc.) and instruction manuals.

The present invention also relates to methods of testing for the presence or absence of resistance to various FGFR inhibitors, prediction of response of a subject to treatment with FGFR inhibitors, or prediction of the effects of FGFR inhibitors in cancer treatment, based on the presence or absence of mutant polypeptides of the present invention or polynucleotides encoding those mutant polypeptides in samples isolated from the subjects.

Specifically, methods of the present invention are, for example, methods of testing and determining the presence or absence of mutant polypeptides of the present invention in samples (tumor tissues, normal tissues, or various body fluids (such as blood, serum, urine, and saliva) that contain cancer cells or normal cells) collected from subjects (cancer patients, those who may have cancer, those at risk of having cancer, or healthy persons, without being limited to humans) by using the above-described methods and kits for detecting the mutant polypeptides of the present invention, and thereby testing for the presence or absence of resistance to various FGFR inhibitors, prediction of response of the subjects to treatment with FGFR inhibitors, or prediction of effects of FGFR inhibitors in cancer treatment, based on the criteria that the presence of the mutant polypeptide indicates the presence of resistance to various FGFR inhibitors.

Furthermore, methods of the present invention are, for example, methods of testing and determining the presence or absence of polynucleotides encoding the mutant polypeptides of the present invention in samples (tumor tissues, normal tissues, or various body fluids (such as blood, serum, urine, and saliva) that contain cancer cells or normal cells) collected from subjects (cancer patients, those who may have cancer, those at risk of having cancer, or healthy persons, without being limited to humans) by using the above-described methods and kits for detecting polynucleotides encoding the mutant polypeptides of the present invention, and thereby testing for the presence or absence of resistance to various FGFR inhibitors, prediction of response of the subjects to treatment with FGFR inhibitors, or prediction of effects of FGFR inhibitors in cancer treatment, based on the criteria that the presence of the mutant polypeptide indicates the presence of resistance to various FGFR inhibitors.

The present invention also relates to methods for selecting a patient to whom an anticancer agent (as described below) containing a compound having FGFR inhibitory activity is applicable, based on the presence or absence of mutant polypeptides of the present invention or polynucleotides encoding the mutant polypeptides in samples isolated from subjects.

Specifically, methods of the present invention are, for example, methods of testing and determining the presence or absence of mutant polypeptides of the present invention in samples (tumor tissues, normal tissues, or various body fluids (such as blood, serum, urine, and saliva) that contain cancer cells or normal cells) collected from subjects (cancer patients or those who may have cancer, without being limited to humans) by using the above-described methods and kits for detecting mutant polypeptides of the present invention, and when the mutant polypeptides are detected, selecting the subject as a patient to whom an anticancer agent (or a pharmaceutical composition for cancer treatment, as described below) containing a compound having FGFR inhibitory activity is applicable. Here, the compound of formula (I) is preferred as the compound having FGFR inhibitory activity. Furthermore, methods of the present invention are, for example, methods of testing and determining the presence or absence of polynucleotides encoding the mutant polypeptides of the present invention in samples (tumor tissues, normal tissues, or various body fluids (such as blood, serum, urine, and saliva) that contain cancer cells or normal cells) collected from subjects (cancer patients or those who may have cancer, without being limited to humans) by using the above-described methods and kits for detecting polynucleotides encoding the mutant polypeptides of the present invention, and when the polynucleotides encoding the mutant polypeptides are detected, selecting the subject as a patient to whom an anticancer agent (as described below) containing a compound having FGFR inhibitory activity is applicable. Here, the compound of formula (I) is preferred as the compound having FGFR inhibitory activity.

In the present invention, “FGFR inhibitor” and “compound having FGFR inhibitory activity” are used interchangeably, and refer to a compound having the activity of inhibiting the activity of the above-mentioned FGFR, specifically, one or more arbitrary FGFRs belonging to the FGFR family comprising FGFR1, FGFR2, FGFR3, and FGFR4, which are fibroblast growth factor receptors (FGFRs) belonging to the receptor tyrosine kinase family. Preferably, they refer to a compound having the activity of inhibiting human FGFR activity, and more preferably a compound having the activity of inhibiting the activity of human FGFR3 comprising the amino acid sequence of SEQ ID NO: 1 or 2 (cDNA sequences, SEQ ID NOs: 3 and 4, respectively/GenBank Accession Nos. NM_000141.4 and NM_022970.3, respectively).

Any FGFR inhibitors are included in the FGFR inhibitors of the present invention as long as the compounds have the activity of inhibiting FGFR activity.

Specifically, the FGFR inhibitors of the present invention include any compounds, antibodies, nucleic acid pharmaceuticals (siRNA, antisense nucleic acids, ribozymes, and such) having an action mechanism of:

(1) inhibiting the FGFR kinase activity; (2) inhibiting dimerization between FGFR, TACC3, and BAIAP2L1;

(3) inhibiting FGFR-mediated signaling (MAPK pathway and PI3K/AKT pathway) (for example, MEK inhibitors, RAF inhibitors, ERK inhibitors, PI3K inhibitors, mTOR inhibitors, AKT inhibitors, PDK inhibitors, S6K inhibitors, etc.); or

(4) inhibiting FGFR expression (for example, siRNA, HSP90 inhibitors, etc.).

Antibodies having the activity of inhibiting FGFR activity, which are included as FGFR inhibitors of the present invention, comprise antibodies identified by the following code names: RG7444, FP-1039, AV370, and PRO-001.

Low-molecular-weight compounds having the activity of inhibiting FGFR activity, which are included as FGFR inhibitors of the present invention, include, for example:

(1) compounds disclosed in the following Patent Document and Non-patent Documents: Cancer Research, 2012, 72: 2045-2056; J. Med. Chem., 2011, 54: 7066-7083; International Publication WO 2011/016528; (2) compounds identified by the following generic names or code names: AZD-4547 (compound C in Table 1 described below), BGJ-398 (compound D in Table 1 described below), LY-2874455, cediranib (AZD2171; compound E in Table 1 described below), PD173074 (compound B in Table 1 described below), regorafenib, ponatinib, orantinib, nintedanib, masitinib, lenvatinib, dovitinib (TKI258), brivanib, volasertib, golvatinib, ENMD-2076, E-3810, XL-999, XL-228, ARQ087, Tivozanib, motesanib, and regorafenib; and (3) compounds exemplified below; however, FGFR inhibitors are not limited thereto:

wherein R₁, R₂, R₃, and R₄ each independently represents the group listed below: R₁ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_(n)Z₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃; R₂ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_(n)Z₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃; or R₁ and R₂, together with an atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl, wherein the heterocyclyl or heteroaryl is optionally substituted by halogen; R₃ represents methyl; R₄ represents hydrogen; A is indole; R₅ represents C₁₋₅ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₃ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₁₋₃ alkoxy C₁₋₄ alkoxy C₁₋₄ alkyl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl C₁₋₃ alkyl, or 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, or C₁₋₆ trihydroxy alkyl which is optionally substituted by one or more groups independently selected from group Q; R₆ and R₇, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₃ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, C₁₋₆ trihydroxy alkyl, 3- to 10-membered heterocyclyl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, or cyano(C₁₋₃ alkyl); or alternatively R₆ and R₇, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; n represents 1 to 3; R₈ and R₉, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, or halogen; or alternatively R₈ and R₉, together with a carbon atom linked thereto, form a cycloaliphatic ring; Z₁ represents hydrogen, NR₁₀R₁₁, —OH, or 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q; R₁₀ and R₁₁, which can be the same or different, each represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, cyano(C₁₋₃ alkyl), or C₁₋₃ alkylsulfonyl C₁₋₄ alkyl; or alternatively R₁₀ and R₁₁, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R₁₂ and R₁₃, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, 3- to 10-membered cycloaliphatic ring, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; or alternatively R₁₂ and R₁₃, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q; R₁₄ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₅ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₆ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₇ represents hydrogen or C₁₋₄ alkyl; R₁₈ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₉ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, haloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₂₉ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₁ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₂ represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl; R₂₃ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₄ represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl; R₂₅ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₆ and R₂₇, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxyl C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively R₂₆ and R₂₇, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R₂₈ and R₂₉, which can be the same or different, each represents hydrogen, C1-4 alkyl, C2-6 alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxyl C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively R₂₈ and R₂₉, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R₃₀ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₃₁represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₃₂ represents C₁₋₄ alkyl or C₆₋₁₀ aryl; <group P> halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, 3- to 10-membered heterocyclylamino, —SO₂R₁₆, —CN, —NO₂, and 3- to 10-membered heterocyclyl; <group Q> halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, C₁₋₆ trihydroxy alkyl, 3- to 10-membered heterocyclyl amine, —SO₂R₁₆, —CN, —NO₂, C₃₋₇ cycloalkyl, —COR₁₉, and 3- to 10-membered heterocyclyl which is optionally substituted by C₁₋₄ alkyl.

Herein, the “alkyl” refers to a monovalent group derived from an aliphatic hydrocarbon by removing an arbitrary hydrogen atom. It contains no heteroatom or unsaturated carbon-carbon bond in the backbone, and has a subset of hydrocarbyl or hydrocarbon group structures which contain hydrogen and carbon atoms. The alkyl group includes linear and branched structures. Preferred alkyl groups include alkyl groups with one to six carbon atoms (C₁₋₆;

hereinafter, “C_(p-q)” means that the number of carbon atoms is p to q), C₁₋₅ alkyl groups, C₁₋₄ alkyl groups, and C₁₋₃ alkyl groups.

Specifically, the alkyl includes, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, s-butyl group, t-butyl group, pentyl group, isopentyl group, 2,3-dimethylpropyl group, 3,3-dimethylbutyl group, and hexyl group.

Herein, “alkenyl” refers to a monovalent hydrocarbon group having at least one double bond (two adjacent SP2 carbon atoms), and includes those of linear and branched forms. Depending on the configuration of the double bond and substituents (if any), the geometry of the double bond can be of entgegen (E) or zusammen (Z), or cis or trans configuration. Preferred alkenyl groups include C₂₆ alkenyl groups.

Specifically, the alkenyl includes, for example, vinyl group, allyl group, 1-propenyl group, 2-propenyl group, 1-butenyl group, 2-butenyl group (including cis and trans), 3-butenyl group, pentenyl group, and hexenyl group.

Herein, “alkynyl” refers to a monovalent hydrocarbon group having at least one triple bond (two adjacent SP carbon atoms), and includes those of linear and branched forms.

Preferred alkynyl groups include C₂₋₆ alkynyl groups.

Specifically, the alkynyl includes, for example, ethynyl group, 1-propynyl group, propargyl group, 3-butynyl group, pentynyl group, and hexynyl group.

The alkenyl and alkynyl may each have one, two or more double bonds or triple bonds.

Herein, “cycloalkyl” refers to a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group, and includes monocyclic groups, bicyclo rings, and spiro rings. Preferred cycloalkyl includes C₃₋₇ cycloalkyl groups. Specifically, the cycloalkyl group includes, for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, and cycloheptyl group.

Herein, “cycloalkylalkyl” refers to a group in which an arbitrary hydrogen atom of an “alkyl” defined above is substituted with a “cycloalkyl” defined above. Preferred cycloalkylalkyl groups include C₃₋₇ cycloalkylC₁₋₃ alkyl, and specifically include, for example, cyclopropylmethyl group and cyclopropylethyl group.

Herein, “hetero atom” refers to a nitrogen atom (N), oxygen atom (O), or sulfur atom (S).

Herein, “halogen” refers to a fluorine atom, chlorine atom, bromine atom, or iodine atom.

Herein, “haloalkyl” refers to a group in which preferably one to nine, more preferably one to five identical or different “halogen atoms” defined above are linked to an “alkyl” defined above.

Specifically, the haloalkyl includes, for example, chloromethyl group, dichloromethyl group, trichloromethyl group, fluoromethyl group, difluoromethyl group, perfluoroalkyl group (such as trifluoromethyl group and —CF₂CF₃), and 2,2,2-trifluoroethyl group.

Herein, “alkoxy” refers to an oxy group linked with an “alkyl” defined above. Preferred alkoxy includes C₁₋₄ alkoxy groups and C₁₋₃ alkoxy groups. Specifically, alkoxy includes, for example, methoxy group, ethoxy group, 1-propoxy group, 2-propoxy group, n-butoxy group, i-butoxy group, sec-butoxy group, and tert-butoxy group.

Herein, “haloalkoxy” refers to a group in which preferably one to nine, more preferably one to five identical or different halogen atoms defined above are linked to an “alkoxy” defined above.

Specifically, the haloalkoxy includes, for example, chloromethoxy group, trichloromethoxy group, and trifluoromethoxy group.

Herein, “aryl” refers to a monovalent aromatic hydrocarbon ring. The aryl preferably includes C₆₋₁₀ aryl. Specifically, the aryl includes, for example, phenyl group and naphthyl groups (for example, 1-naphthyl group and 2-naphthyl group).

Herein, “alicyclic ring” refers to a monovalent non-aromatic hydrocarbon ring. The alicyclic ring may have unsaturated bonds within its ring, and may be a multicyclic group having two or more rings. The carbon atoms constituting the ring may be oxidized to form a carbonyl. The number of atoms constituting an alicyclic ring preferably ranges from three to ten (3- to 10-membered aliphatic ring). The alicyclic ring includes, for example, cycloalkyl rings, cycloalkenyl rings, and cycloalkynyl rings.

Herein, “heteroaryl” refers to a monovalent aromatic heterocyclic group in which the ring-constituting atoms include preferably one to five hetero atoms. The heteroaryl may be partially saturated, and may be a monocyclic or condensed ring (for example, a bicyclic heteroaryl condensed with a benzene ring or monocyclic heteroaryl ring). The number of ring-constituting atoms preferably ranges from five to ten (5- to 10-membered heteroaryl).

Specifically, the heteroaryl includes, for example, furyl group, thienyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, thiazolyl group, isothiazolyl group, oxazolyl group, isooxazolyl group, oxadiazolyl group, thiadiazolyl group, triazolyl group, tetrazolyl group, pyridyl group, pyrimidyl group, pyridazinyl group, pyrazinyl group, triazinyl group, benzofuranyl group, benzothienyl group, benzothiadiazolyl group, benzothiazolyl group, benzoxazolyl group, benzoxadiazolyl group, benzoimidazolyl group, indolyl group, isoindolyl group, azaindolyl group, indazolyl group, quinolyl group, isoquinolyl group, cinnolinyl group, quinazolinyl group, quinoxalinyl group, benzodioxolyl group, indolidinyl group, and imidazopyridyl group.

Herein, “heterocyclyl” refers to a non-aromatic monovalent heterocyclic group in which the ring-constituting atoms include preferably one to five hetero atoms. The heterocyclyl may contain double or triple bonds in its ring. The carbon atoms may be oxidized to form carbonyl. The ring may be a monocyclic or condensed ring. The number of the ring-constituting atoms preferably ranges from three to ten (3- to 10-membered heterocyclyl).

Specifically, the heterocyclyl includes, for example, oxetanyl group, dihydrofuryl group, tetrahydrofuryl group, dihydropyranyl group, tetrahydropyranyl group, tetrahydropyridyl group, morpholinyl group, thiomorpholinyl group, pyrrolidinyl group, piperidinyl group, piperazinyl group, pyrazolidinyl group, imidazolinyl group, imidazolidinyl group, oxazolidinyl group, isooxazolidinyl group, thiazolidinyl group, isothiazolidinyl group, thiadiazolidinyl group, azetidinyl group, oxazolidone group, benzodioxanyl group, benzoxazolyl group, dioxolanyl group, and dioxanyl group.

Herein, “arylalkyl” refers to a group in which an arbitrary hydrogen atom in an “alkyl” defined above is substituted with an “aryl” defined above. The arylalkyl preferably includes C₆₋₁₀ aryl C₁₋₄ alkyl and C₆₋₁₀ aryl C₁₋₃ alkyl. Specifically, the arylalkyl includes, for example, benzyl group, phenethyl group, and naphthylmethyl group.

Herein, “heteroarylalkyl” refers to a group in which an arbitrary hydrogen atom in an alkyl defined above is substituted with a “heteroaryl” defined above. The heteroarylalkyl preferably includes 5- to 10-membered heteroaryl C₁₋₃ alkyl. Specifically, the heteroarylalkyl includes, for example, pyrrolylmethyl group, imidazolylmethyl group, thienylmethyl group, pyridylmethyl group, pyrimidylmethyl group, quinolylmethyl group, and pyridylethyl group.

Herein, “heterocyclylalkyl” refers to a group in which an arbitrary hydrogen atom in an “alkyl” defined above is substituted with a “heterocyclyl” defined above. The heterocyclylalkyl preferably includes 3- to 10-membered heterocyclyl C₁₋₃ alkyl. Specifically, the heterocyclylalkyl includes, for example, morpholinylmethyl group, morpholinylethyl group, thiomorpholinylmethyl group, pyrrolidinylmethyl group, piperidinylmethyl group, piperazinylmethyl group, piperazinylethyl group, and oxetanylmethyl group.

Herein, “monohydroxyalkyl” refers to a group in which an arbitrary hydrogen atom in an “alkyl” defined above is substituted with a hydroxyl group. The monohydroxyalkyl preferably includes C₁₋₆ monohydroxyalkyl and C₂₋₆ monohydroxyalkyl. Specifically, the monohydroxyalkyl includes, for example, hydroxymethyl group, 1-hydroxyethyl group, and 2-hydroxyethyl group.

Herein, “dihydroxyalkyl” refers to a group in which two arbitrary hydrogen atoms in an “alkyl” defined above are substituted with two hydroxyl groups. The dihydroxyalkyl preferably includes C₁₋₆ dihydroxyalkyl and C₂₋₆ dihydroxyalkyl. Specifically, the dihydroxyalkyl includes, for example, 1,2-dihydroxyethyl group, 1,2-dihydroxypropyl group, and 1,3-dihydroxypropyl group.

Herein, “trihydroxyalkyl” refers to a group in which three arbitrary hydrogen atoms in an “alkyl” defined above are substituted with three hydroxyl groups. The trihydroxyalkyl preferably includes C₁₋₆ trihydroxyalkyl and C₂₋₆ trihydroxyalkyl.

Herein, “alkoxyalkyl” refers to a group in which an arbitrary hydrogen atom in an “alkyl” defined above is substituted with an “alkoxy” defined above. The alkoxyalkyl preferably includes C₁₋₃ alkoxy C₁₋₄ alkyl and C₁₋₃ alkoxy C₂₋₄ alkyl. Specifically, the alkoxyalkyl includes, for example, methoxyethyl.

Herein, “alkoxyalkoxyalkyl” refers to a group in which an arbitrary hydrogen atom in the terminal alkyl of an “alkoxyalkyl” defined above is substituted with an “alkoxy” defined above. The alkoxyalkoxyalkyl preferably includes C₁₋₃ alkoxy C₁₋₄ alkoxy C₁₋₄ alkyl and C₁₋₃ alkoxy C₂₋₄ alkoxy C₂₋₄ alkyl.

Herein, “aminoalkyl” refers to a group in which an arbitrary hydrogen atom in an “alkyl” defined above is substituted with an amino group. The aminoalkyl group preferably includes C₁₋₄ aminoalkyl and C₂₋₄ aminoalkyl.

Herein, “alkylamino” refers to an amino group linked with an “alkyl” defined above. The alkylamino preferably includes C₁₋₄ alkylamino.

Herein, “dialkylamino” refers to an amino group linked with two “alkyls” defined above. The two alkyl groups may be same or different. The dialkylamino preferably includes di(C₁₋₄ alkyl)amino.

Herein, “alkylaminoalkyl” refers to a group in which an arbitrary hydrogen atom in an “alkyl” defined above is substituted with an “alkylamino” defined above. The alkylaminoalkyl preferably includes C₁₋₄ alkylamino C₁₋₄ alkyl and C₁₋₄ alkylamino C₂₋₄ alkyl.

Herein, “dialkylaminoalkyl” refers to a group in which an arbitrary hydrogen atom in an “alkyl” defined above is substituted with a “dialkylamino” defined above. The dialkylaminoalkyl preferably includes di(C₁₋₄ alkyl)amino C₁₋₄ alkyl and di(C₁₋₄ alkyl)amino C₂₋₄ alkyl.

Herein, “heterocyclylamino” refers to an amino group linked with a “heterocyclyl” defined above. The heterocyclylamino preferably includes 3- to 10-membered heterocyclylamino.

Herein, “cyanoalkyl” refers to a group in which an arbitrary hydrogen atom in an “alkyl” defined above is substituted with a cyano group. The cyanoalkyl preferably includes cyano(C₁₋₃ alkyl).

Herein, “alkylsulfonyl” refers to a sulfonyl group linked with an “alkyl” defined above (i.e. alkyl-SO₂—). The alkylsulfonyl preferably includes C₁₋₃ alkylsulfonyl. Specifically, the alkylsulfonyl includes methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, and i-propylsulfonyl.

Herein, “alkylsulfonylalkyl” refers to a group in which an arbitrary hydrogen atom in an “alkyl” defined above is substituted with an “alkylsulfonyl” defined above. The alkylsulfonylalkyl preferably includes C₁₋₃ alkylsulfonyl C₁₋₄ alkyl and C₁₋₃ alkylsulfonyl C2-4 alkyl.

Preferably, the compounds represented by formula (I) shown above are as follows:

R₁ shown above preferably represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_(n)Z₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃.

R₁ shown above more preferably represents hydrogen, hydroxy, halogen, cyano, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_(n)Z₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q. Specifically, the above 5- to 10-membered heteroaryl is particularly preferably an imidazolyl group, thienyl group, pyridyl group, pyridazinyl group, or pyrazolyl group. The above 3- to 10-membered heterocyclyl is particularly preferably a morpholinyl group, tetrahydropyridyl group, or piperidinyl group.

R₂ shown above preferably represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_(n)Z₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO2R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃.

R₂ shown above more preferably represents hydrogen, halogen, C₁₋₄ haloalkyl, C₁₋₆ alkyl, —OR₅, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl which is optionally substituted with one or more groups independently selected from group Q. Specifically, this 5- to 10-membered heteroaryl is particularly preferably a pyridyl group.

R₁ and R₂ shown above can preferably be taken together with the atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl. The heterocyclyl or heteroaryl may have a halogen atom as a substituent. Specifically, the 3- to 10-membered heterocyclyl formed together with the atoms to which R₁ and R₂ are attached, is particularly preferably a dioxolanyl group or dioxanyl group.

R₃ shown above preferably represents hydrogen, C₁₋₅ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, or C₁₋₄ haloalkyl, more preferably hydrogen, C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, or C₁₋₃perfluoroalkyl, and particularly preferably C₁ alkyl.

R₄ shown above preferably represents hydrogen, halogen, C₁₋₃ alkyl, C₁₋₄ haloalkyl, hydroxy, cyano, nitro, C₁₋₄ alkoxy, —(CH₂)_(n)Z₁, —NR₆R₇, —OR₅, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, NR₁₇SO₂R₁₈, COOH, —COOR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀—SO₃R₃₁, or —Si(R₃₂)₃.

R₄ shown above more preferably represents hydrogen, halogen, C₁₋₃ alkyl, C₁₋₃ perfluoroalkyl, cyano, methanesulfonyl, hydroxyl, alkoxy, or amino, and particularly preferably hydrogen or halogen.

Ring A mentioned above is preferably a 5- to 10-membered heteroaryl ring or C₆₋₁₀ aryl ring, more preferably benzene, indole, azaindole, benzofuran, benzothiophene, benzothiazole, quinoline, or pyrrole, and particularly preferably indole or pyrrole.

R₅ shown above preferably represents C₁₋₅ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₃ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₁₋₃ alkoxy C₁₋₄ alkoxy C₁₋₄ alkyl, C₁₋₄ amino alkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl C₁₋₃ alkyl, or 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl C₁₋₃ alkyl, each of which is optionally substituted with one or more groups independently selected from group Q, C₁₋₆ monohydroxyalkyl, C₁₋₆ dihydroxyalkyl, or C₁₋₆ trihydroxyalkyl.

R₅ shown above more preferably represents C₁₋₅ alkyl, C₃₋₇ cycloalkyl C₁₋₃ alkyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl , C₆₋₁₀ aryl C₁₋₃ alkyl, or 3- to 10-membered heterocyclyl C₁₋₃ alkyl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q. Specifically, the above 3- to 10-membered heterocyclylalkyl is particularly preferably a piperazinylethyl group, oxetanylmethyl group, or morpholinylethyl group. The above 3- to 10-membered heterocyclyl is particularly preferably an oxetanyl group or tetrahydropyranyl group.

R₆ and R₇ shown above may be the same or different, and each preferably represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₂₋₄ alkyl, C₆₋₁₀ aryl C₁₋₃ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxyalkyl, C₁₋₆ dihydroxyalkyl, C₁₋₆ trihydroxyalkyl, 3- to 10-membered heterocyclyl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋ ₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, or cyano(C₁₋₃ alkyl).

R₆ and R₇ shown above more preferably each independently represent hydrogen, C₁₋₃ alkoxy C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, or C₁₋₆ dihydroxyalkyl. Specifically, the 3- to 10-membered heterocyclylalkyl is particularly preferably a morpholinylethyl group, and the 5- to 10-membered heteroarylalkyl is particularly preferably a pyridylethyl group.

Alternatively, R6 and R7 shown above can preferably be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl.

“n” shown above represents an integer from 1 to 3. Preferably, n is 1.

R₈ and R₉ shown above preferably may be the same or different, and each represents hydrogen, C₁₋₄ alkyl, or halogen, and more preferably hydrogen.

Alternatively, R₈ and R₉ shown above can preferably be taken together with the carbon atoms to which they are attached to form an alicyclic ring.

Z₁ shown above preferably represents hydrogen, NR₁₀R₁₁, —OH, or 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl each of which is optionally substituted with one or more groups independently selected from group Q, more preferably NR₁₀R₁₁ or —OH, or 3- to 10-membered heterocyclyl which is optionally substituted with one or more groups independently selected from group Q. Specifically, the above 3- to 10-membered heterocyclyl is particularly preferably a pyrrolidinyl group, piperazinyl group, piperidinyl group, or morpholinyl group.

R₁₀ and R₁₁ shown above preferably may be the same or different, and each preferably represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, cyano(C₁₋₃ alkyl), or C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, more preferably C₁₋₄ alkyl, C₂₋₆ alkynyl, or C₁₋₃ alkoxy C₂₋₄ alkyl.

Alternatively, R₁₀ and R₁₁ shown above can preferably be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl.

R₁₂ and R₁₃ shown above preferably may be the same or different, and each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₉ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₉ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C1-3 alkyl, cyano(C1-3 alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered alicyclic ring, more preferably hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl.

Alternatively, R₁₂ and R₁₃ shown above preferably can be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl each of which is optionally substituted with one or more groups independently selected from group Q, and particularly preferably 3- to 10-membered heterocyclylalkyl. Specifically, piperazinyl group, morpholinyl group, pyrrolidinyl group, and piperidinyl group are more preferred.

R₁₄ shown above preferably represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents C₁₋₄ alkyl or C₁₋₄ haloalkyl.

R15 shown above preferably represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q.

R₁₆ shown above preferably represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents C₁₋₄ alkyl.

R₁₇ shown above preferably represents hydrogen or C₁₋₄ alkyl, and more preferably hydrogen.

R₁₈ shown above preferably represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents C₁₋₄ alkyl.

R₁₉ shown above preferably represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents hydrogen, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q. Specifically, this 3- to 10-membered heterocyclyl is more preferably a piperazinyl group, morpholinyl group, pyrrolidinyl group, or piperidinyl group.

R₂₀ shown above preferably represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

R₂₁ shown above preferably represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

R₂₂ shown above preferably represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl.

R₂₃ shown above preferably represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

R₂₄ shown above preferably represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl.

R₂₅ shown above preferably represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

R₂₆ and R₂₇ shown above preferably may be the same or different, and each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₄ alkyl, or 3- to 10-membered alicyclic ring.

Alternatively, R₂₆ and R₂₇ shown above can preferably be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl.

R₂₈ and R₂₉ shown above preferably may be the same or different, and each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered alicyclic ring.

Alternatively, R₂₈ and R₂₉ shown above preferably can be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl.

R₃₀ shown above preferably represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

R₃₁ shown above preferably represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.

R₃₂ shown above preferably represents C₁₋₄ alkyl, or C₆₋₁₀ aryl.

Preferred substituents included in group P defined above are halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, 3- to 10-membered heterocyclylamino, —SO₂R, —CN, —NO₂, and 3- to 10-membered heterocyclyl; and more preferably halogen, C₁₋₄ haloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, and 3- to 10-membered heterocyclyl. Specifically, this 3- to 10-membered heterocyclyl is particularly preferably a morpholinyl group.

Preferred substituents included in group Q defined above are halogen, C₁₋₄ alkyl, C1-4 haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₆ monohydroxyalkyl, C₁₋₆ dihydroxyalkyl, C₁₋₆ trihydroxyalkyl, 3- to 10-membered heterocyclylamino, —SO₂R, —CN, —NO₂, C₃₋₇ cycloalkyl, -COR19, and 3- to 10-membered heterocyclyl which is optionally substituted with C₁₋₄ alkyl; and more preferably halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₆ monohydroxyalkyl, —SO₂R₁₆, C₃₋₇ cycloalkyl, —COR₁₉, and 3- to 10-membered heterocyclyl which is optionally substituted with C₁₋₄ alkyl. Specifically, this 3- to 10-membered heterocyclyl is more preferably a piperazinyl group, piperidinyl group, or morpholinyl group.

Specific examples of the compounds include:

(1) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone; (2) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyrrolidin-1-ylmethyl-1H-indol-2-yl)-methanone; (3) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-hydroxy-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (4) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-pyrrolo[3,2-c]pyridin-2-yl)-methanone; (5) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(6-piperazin-1-ylmethyl-1H-indol-2-yl)-methanone; (6) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morpholin-4-yl-ethoxy)-1H-indol-2-yl]-methanone; (7) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(tetrahydro-pyran-4-yloxy)-1H-indol-2-yl]-methanone; (8) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-chloro-1H-indol-2-yl)-methanone; (9) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-bromo-1H-indol-2-yl)-methanone; (10) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-iodo-1H-indol-2-yl)-methanone; (11) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carbonitrile; (12) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl] -(6-bromo-5-fluoro-1H-indol-2-yl)-methanone; (13) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-ethynyl-1H-indo1-2-yl)-methanone; (14) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone; (15) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-phenyl)-1H-indol-2-yl]-methanone; (16) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-phenyl)-1H-indol-2-yl]-methanone; (17) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-chloro-phenyl)-1H-indol-2-yl]-methanone; (18) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-phenyl)-1H-indol-2-yl]-methanone; (19) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chloro-phenyl)-1H-indol-2-yl]-methanone; (20) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone; (21) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone; (22) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone; (23) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-bromo-1H-indol-2-yl)-methanone; (24) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone; (25) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-methyl-1H-indol-2-yl)-methanone; (26) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone; (27) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone; (28) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carboxylic acid (2,2,2-trifluoro-ethyl)-amide; (29) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone; (30) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone; (31) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone; (32) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-pyridin-2-yl)-1H-indol-2-yl]methanone; (33) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-4-fluoro-phenyl)-1H-indol-2-yl]-methanone; (34) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone; (35) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]methanone; (36) [5-amino-1-(6-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone; (37) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carboxylic acid; (38) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-hydroxymethyl-1H-indol-2-yl)-methanone; (39) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[2-(4-methyl-piperazin-1-yl)-ethoxy]-1H-indol-2-yl}- methanone; (40) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-methyl-oxetan-3-ylmethoxy)-1H-indol-2-yl]-methanone; (41) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (42) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-{[bis(2-methoxy-ethyl)-amino]-methyl}-1H-indol-2-yl)-methanone; (43) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[(methyl-prop-2-ynyl-amino)-methyl]-1H-indol-2-yl}-methanone; (44) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (45) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (46) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (47) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((S)-3-methyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone; (48) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-bromo-1H-indol-2-yl)-methanone; (49) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-iodo-1H-indo1-2-yl)-methanone; (50) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-pyrrolo[3,2-b]pyridin-2-yl)-methanone; (51) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-bromo-6-trifluoromethyl-1H-indol-2-yl)-methanone; (52) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-iodo-1H-indol-2-yl)-methanone; (53) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-methyl-1H-indol-2-yl)-methanone; (54) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-isopropyl-1H-indol-2-yl)-methanone; (55) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone; (56) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-benzyl-1H-indol-2-yl)-methanone; (57) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone; (58) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluorophenyl)-1H-indol-2-yl]-methanone; (59) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone; (60) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-ethynyl-1H-indol-2-yl)-methanone; (61) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5H[1,3]dioxolo[4,5-f]indol-6-yl)-methanone; (62) [5-amino-1-(7-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone; (63) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone; (64) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-butoxy-1H-indol-2-yl)-methanone; (65) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]methanone; (66) N-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-6-yl}-methanesulfonamide; (67) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morpholin-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone; (68) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-butyl-1H-indol-2-yl)-methanone; (69) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-methanone; (70) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone; (71) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone; (72) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-cyclopropyl-1H-indol-2-yl)-methanone; (73) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-phenyl)-1H-indol-2-yl]-methanone; (74) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-phenyl-1H-indol-2-yl)-methanone; (75) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methanesulfonyl-pyridin-3-yl)-1H-indol-2-yl]-methanone; (76) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-isopropyl-1H-indol-2-yl)-methanone; (77) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyridin-2-yl-1H-indol-2-yl)-methanone; (78) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-cyclopropyl-1H-indol-2-yl)-methanone; (79) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyridazin-3-yl-1H-indol-2-yl)-methanone; (80) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-isopropoxy-1H-indol-2-yl)-methanone; (81) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-methoxy-ethoxy)-1H-indol-2-yl]-methanone; (82) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-cyclopropylmethoxy-1H-indol-2-yl)-methanone; (83) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(2,2-difluoro-5H-[1,3]dioxolo[4,5-f]indol-6-yl)-methanone; (84) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone; (85) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone; (86) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morpholin-4-yl-pyridazin-3-yl)-1H-indol-2-yl]-methanone; (87) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-chloro-6-cyclopropylmethoxy-1H-indol-2-yl)-methanone; (88) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,4-difluoro-phenyl)-1H-indo1-2-yl]-methanone; (89) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyridazin-4-yl-1H-indol-2-yl)-methanone; (90) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(3-fluoro-1H-indol-2-yl)-methanone; (91) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-6-trifluoromethyl-1H-indl-2-yl]- methanone; (92) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carbonitrile; (93) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-2-yl]-methanone; (94) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-piperidin-4-yl-1H-indol-2-yl)-methanone; (95) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (96) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-fluoro-5-piperidin-4-yl-1H-indol-2-yl)-methanone; (97) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (98) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (99) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (100) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyridin-3-yl-1H-indol-2-yl)-methanone; (101) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-morpholin-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone; (102) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-pyridin-3-yl-1H-indol-2-yl)-methanone; (103) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-piperazin-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone; (104) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-hydroxy-pyridin-3-yl)-1H-indol-2-yl]-methanone; (105) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]- methanone; (106) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-fluoro-5-pyrrolidin-1-ylmethyl-1H-indol-2-yl)-methanone; (107) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (108) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-morpholin-4-yl-phenyl)-1H-indol-2-yl]-methanone; (109) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,4,5,6-tetrahydro-2H-[1,2′]bipyridin-5′-yl)-1H-indol- 2-yl]-methanone; (110) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-piperazin-1-yl-pyridin-3-yl)-1H-indo1-2-yl]-methanone; (111) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone; (112) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((S)-3-methyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone; (113) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (114) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (115) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (116) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (117) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[2-(4-methyl-piperazin-1-yl)pyridin-4-yl]-1H-indol-2- yl}-methanone; (118) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyridin-4-yl-1H-indol-2-yl)-methanone; (119) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-fluoropiperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (120) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (121) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (122) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone; (123) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indo1-2-yl]-methanone; (124) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclopentyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (125) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[45-(1-cyclohexyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (126) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-bromo-1H-pyrrol-2-yl)-methanone; (127) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-pyrrol-2-yl)-methanone; (128) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(4-phenyl-1H-pyrrol-2-yl)-methanone; (129) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-chloro-phenyl)-1H-pyrrol-2-yl]-methanone; (130) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone; (131) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone; (132) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-morpholin-4-ylmethyl-1H-indol-2-yl)-methanone; (133) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-morpholin-4-yl-ethylamino)-1H-indol-2-yl]-methanone; (134) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-piperazine-1-carbonyl)-1H-indol-2-yl]-methanone; (135) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morpholin-4-yl-ethylamino)-1H-indol-2-yl]-methanone; (136) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(piperazine-1-carbonyl)-1H-indol-2-yl]-methanone; (137) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-methoxy-ethylamino)-1H-indol-2-yl]-methanone; (138) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-1H-indol-2-yl]-methanone; (139) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-pyridin-4-yl-ethylamino)-1H-indol-2-yl]-methanone; (140) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-ethylamino)-1H-indol-2-yl]-methanone; (141) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-morpholin-4-yl-1H-indol-2-yl)-methanone; (142) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-morpholin-4-yl-1H-indol-2-yl)-methanone; (143) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-morpholin-4-ylmethyl-1H-indol-2-yl)-methanone; (144) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-morpholin-4-ylmethyl-1H-indol-2-yl)-methanone; (145) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(morpholine-4-carbonyl)-1H-indol-2-yl]-methanone; (146) [5-amino-1-(2-isopropyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone; (147) [5-amino-1-(2-propyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone; (148) [5-amino-1-(1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone; (149) [5-amino-1-(2-trifluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone; (150) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl] -(1H-indol-2-yl)-methanone; (151) [5-amino-1-(2-benzyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)methanone; (152) 1-(4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-5-ylmethyl}-piperazin-1-yl)-ethanone; (153) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone; (154) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[(5-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone; (155) 1-(4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-6-ylmethyl}-piperazin-1-yl)-ethanone; (156) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone; (157) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone; (158) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-pyrrolidin-1-ylmethyl-1H-indol-2-yl)-methanone; (159) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-fluoro-1H-indol-2-yl)-methanone; (160) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-fluoro-1H-indol-2-yl)-methanone; (161) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-fluoro-1H-indol-2-yl)-methanone; (162) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-pyrrolo [2,3-b]pyridin-2-yl)-methanone; (163) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(5-fluoro-6-morpholin-4-ylmethyl-1H-indol-2-yl)-methanone; (164) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carboxylic acid; (165) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-methoxy-1H-indol-2-yl)-methanone; (166) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,6-dimethoxy-1H-indol-2-yl)-methanone; (167) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-methoxy-1H-indol-2-yl)-methanone; (168) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-methoxy-1H-indol-2-yl)-methanone; (169) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(4,6-dimethyl-1H-indol-2-yl)-methanone; (170) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-tert-butyl-1H-indol-2-yl)-methanone; (171) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-isopropyl-1H-indol-2-yl)-methanone; (172) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-benzyloxy-1H-indol-2-yl)-methanone; (173) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-benzyloxy-1H-indol-2-yl)-methanone; (174) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5,6-dimethoxy-1H-indol-2-yl)-methanone; (175) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-tert-butyl-1H-indol-2-yl)-methanone; (176) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-fluoro-4-trifluoromethyl-1H-indol-2-yl)-methanone; (177) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-phenoxy-1H-indol-2-yl)-methanone; (178) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-methylsulfanyl-1H-indol-2-yl)-methanone; (179) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-tert-butyl-1H-indol-2-yl)-methanone; (180) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-methyl-1H-indol-2-yl)-methanone; (181) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-ethyl-1H-indol-2-yl)-methanone; (182) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-fluoro-6-trifluoromethyl-1H-indol-2-yl)-methanone; (183) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-fluoro-5-methoxy-1H-indol-2-yl)-methanone; (184) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-chloro-5-methoxy-1H-indol-2-yl)-methanone; (185) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-chloro-6-methoxy-1H-indol-2-yl)-methanone; (186) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-isopropoxy-1H-indol-2-yl)-methanone; (187) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-benzyloxy-1H-indol-2-yl)-methanone; (188) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-isopropoxy-1H-indol-2-yl)-methanone; (189) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(2,3-dihydro-6H-[1,4]dioxino [2,3-f]indol-7-yl)-methanone; (190) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,6-di-tert-butyl-1H-indol-2-yl)-methanone; (191) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-4-carbonitrile; (192) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-imidazol-1-yl-1H-indol-2-yl)-methanone; (193) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-trifluoromethylsulfanyl-1H-indol-2-yl)-methanone; (194) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(5-methylsulfanyl-1H-indol-2-yl)-methanone; (195) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-methanesulfonyl-1H-indol-2-yl)-methanone; (196) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-[6-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (197) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (198) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(oxetan-3-yloxy)-1H-indol-2-yl]-methanone; (199) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-hydroxy-1H-indol-2-yl)-methanone; (200) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-methanesulfonyl-1H-indol-2-yl)-methanone; (201) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,5-dibromo-1H-pyrrol-2-yl)-methanone; (202) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,5-diphenyl-1H-pyrrol-2-yl)-methanone; and (203) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,5-dipyridin-3-yl-1H-pyrrol-2-yl)-methanone. (204) [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-chloro-1H-indol-2-yl)-methanone; (205) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-chloro-1H-indol-2-yl)-methanone; (206) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-3-yl)-methanone; (207) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-6-yl)-methanone; (208) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(5-bromo-6-fluoro-1H-indol-2-yl)-methanone; (209) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-bromo-6-fluoro-1H-indol-2-yl)-methanone; (210) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-trifluoromethyl-1H-indol-2-yl)-methanone; (211) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-trifluoromethoxy-1H-indol-2-yl)-methanone; (212) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,6-dichloro-1H-indo1-2-yl)-methanone; (213) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-bromo-4-fluoro-1H-indol-2-yl)-methanone; (214) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-trifluoromethoxy-1H-indol-2-yl)-methanone; (215) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-trifluoromethoxy-1H-indol-2-yl)-methanone; (216) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-trifluoromethyl-1H-indol-2-yl)-methanone; (217) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5,6-dichloro-1H-indol-2-yl)-methanone; (218) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-bromo-5-fluoro-1H-indol-2-yl)-methanone; (219) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,5-dichloro-1H-indol-2-yl)-methanone; (220) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,6-difluoro-1H-indo1-2-yl)-methanone; (221) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-pyridin-4-yl)-1H-indol-2-yl]-methanone; (222) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-methyl-pyridine-3-yl)-1H-indol-2-yl]-methanone; (223) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-pyridin-3-yl)-1H-indol-2-yl]-methanone; (224) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-pyridin-3-yl)-1H-indol-2-yl]-methanone; (225) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-2-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone; (226) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-3-yl)-1H-indol-2-yl]-methanone; (227) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-thiophen-3-yl-1H-indol-2-yl)-methanone; (228) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chloropyridin-3-yl)-1H-indol-2-yl]-methanone; (229) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(6-thiophen-2-yl-1H-indol-2-yl)-methanone; (230) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-pyridin-4-yl)-1H-indol-2-yl]-methanone; (231) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-pyridin-4-yl)-1H-indol-2-yl]-methanone; (232) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone; (233) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,6-dimethyl-morpholine-4-carbonyl)-1H-indol-2-yl]-methanone; (234) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-([1,4] bipiperidinyl-1′-carbonyl)-1H-indol-2-yl]-methanone; (235) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{5-[4-(2,2,2-trifluoro-ethyl)-piperazine-1-carbonyl]-1H-indol-2- yl}-methanone; (236) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{5-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-1H-indol-2-yl}-methanone; (237) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3,4,4-tetrafluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]- methanone; (238) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-fluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone; (239) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((S)-3-fluroro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone; (240) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone; (241) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone; (242) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone; (243) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone; (244) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2,4-difluoro-phenyl)-1H-pyrrol-2-yl]-methanone; (245) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-trifluoromethoxy-phenyl)-1H-pyrrol-2-yl]-methanone; (246) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone; (247) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzofuran-2-yl-methanone; (248) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzo[b] thiophen-2-yl-methanone; (249) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzothiazol-2-yl-methanone; (250) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-fluoro-phenyl)-methanone; (251) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(3-chloro-phenyl)-methanone; (252) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-3-yl-methanone; (253) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-7-yl-methanone; and (254) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-6-yl-methanone.

More specific examples include compounds in which A is indole, R3 is methyl, and R4 is hydrogen in formula (I) described above, and compounds shown in Table 1 can be included as examples.

TABLE 1 CODE STRUCTURAL FORMULA/CHEMICAL NAME A

B

C

D

E

The above-mentioned compounds can be produced according to the production method described in International Publication WO 2011/016528.

In the present invention, compounds having FGFR inhibitory activity as describe above include not only free forms but also pharmaceutically acceptable salts thereof.

Such “salts” include, for example, inorganic acid salts, organic salts, inorganic base salts, organic base salts, and acidic or basic amino acid salts. Preferred inorganic acid salts include, for example, hydrochloride, hydrobromide, sulfate, nitrate, and phosphate. Preferred organic salts include, for example, acetate, succinate, fumarate, maleate, tartrate, citrate, lactate, malate, stearate, benzoate, methanesulfonate, and p-toluenesulfonate. A particularly preferred salt in the present invention is malate.

Preferred inorganic base salts include, for example, alkali metal salts such as sodium salts and potassium salts; alkali earth metal salts such as calcium salts and magnesium salts; aluminum salts; and ammonium salts. Preferred organic base salts include, for example, diethylamine salts, diethanolamine salts, meglumine salts, and N,N-dibenzylethylenediamine salts.

Preferred acidic amino acid salts include, for example, aspartate and glutamate. Preferred basic amino acid salts include, for example, arginine salts, lysine salts, and ornithine salts.

In the present invention, compounds having FGFR inhibitory activity also include hydrates thereof Furthermore, in the present invention, compounds having FGFR inhibitory activity may absorb some type of solvents to form solvates. Such solvates are also included.

In addition, compounds having FGFR inhibitory activity in the present invention include all possible structural isomers (geometric isomers, optical isomers, stereoisomers, tautomers, etc.), and mixtures of isomers.

Compounds having FGFR inhibitory activity in the present invention also include any crystalline polymorphism thereof.

In the present invention, compounds having FGFR inhibitory activity also include prodrugs thereof “Prodrug” refers to derivatives of the compounds of the present invention which have a chemically or metabolically degradable group, and upon administration to the living body, revert to the original compounds and exhibit the original drug efficacy. The prodrugs include non-covalent complexes and salts. In the present invention, compounds having FGFR inhibitory activity include those in which one or more atoms within the molecule have been replaced with isotopes. Herein, “isotope” refers to an atom which has the same atomic number (proton number) but different mass number (sum of protons and neutrons). The target atoms to be replaced with an isotope in the compounds of the present invention include, for example, hydrogen atom, carbon atom, nitrogen atom, oxygen atom, phosphorus atom, sulfur atom, fluorine atom, and chlorine atom. Their isotopes include ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁷O, ¹⁸O, ³¹P, ³²P, ³⁵S, ¹⁸F, and ³⁶Cl. In particular, radioisotopes such as ³H and ¹⁴C, which emit radiation and decay, are useful in in vivo tissue distribution studies or such of pharmaceuticals or compounds. Stable isotopes do not decay, and thus their quantity rarely changes; and since there is no emission of radiation, stable isotopes can be used safely. The compounds of the present invention can be converted into isotope-substituted compounds according to routine methods by replacing reagents used in synthesis with reagents containing corresponding isotopes.

Herein, “anticancer agent” or “pharmaceutical composition for treating cancer” which comprises an FGFR inhibitor are used interchangeably, and refers to a cancer therapeutic composition that comprises an above-described compound having FGFR inhibitory activity and pharmaceutically acceptable carriers.

The compounds having FGFR inhibitory activity of the present invention can be formulated into tablets, powders, fine granules, granules, coated tablets, capsules, syrups, troches, inhalants, suppositories, injections, ointments, eye ointments, eye drops, nasal drops, ear drops, cataplasms, lotions, and such by routine methods. For the formulation, conventional excipients, binders, lubricants, colorants, flavoring agents, and if needed, stabilizers, emulsifiers, absorbefacients, surfactants, pH adjusting agents, preservatives, antioxidants, and such can be used. The compounds of the present invention are formulated using routine methods, by combining ingredients that are generally used as materials for pharmaceutical preparations.

For example, to produce oral formulations, the compounds of the present invention or pharmacologically acceptable salts thereof are combined with excipients, and if needed, binders, disintegrating agents, lubricants, coloring agents, flavoring agents, and the like; and then formulated into powders, fine granules, granules, tablets, coated tablets, capsules, and such by routine methods.

The ingredients include, for example, animal and vegetable oils such as soybean oils, beef tallow, and synthetic glycerides; hydrocarbons such as liquid paraffin, squalane, and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenyl alcohol; silicon resins; silicon oils; surfactants such as polyoxyethylene fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oils, and polyoxyethylene/polyoxypropylene block copolymers; water-soluble polymers such as hydroxyethyl cellulose, polyacrylic acids, carboxyvinyl polymers, polyethylene glycol, polyvinylpyrrolidone, and methyl cellulose; lower alcohols such as ethanol and isopropanol; polyalcohols such as glycerin, propylene glycol, dipropylene glycol, and sorbitol; saccharides such as glucose and sucrose; inorganic powders such as silicic anhydride, magnesium aluminum silicate, and aluminum silicate; and purified water.

Excipients include, for example, lactose, cornstarch, sucrose, glucose, mannitol, sorbit, crystalline cellulose, and silicon dioxide.

Binders include, for example, polyvinyl alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, Arabic gum, tragacanth, gelatin, shellac, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polypropylene glycol/polyoxyethylene block polymer, and meglumine.

Disintegrating agents include, for example, starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextran, pectin, and calcium carboxymethyl cellulose.

Lubricants include, for example, magnesium stearate, talc, polyethylene glycol, silica, and hardened vegetable oil.

Coloring agents approved for use as additives for pharmaceuticals are used. Flavoring agents used include, for example, cacao powder, menthol, aromatic powder, peppermint oil, borneol, and cinnamon powder.

Of course, these tablets and granules may be coated with sugar, or if needed, other appropriate coatings. Alternatively, when liquid preparations such as syrups and injections are produced, the compounds of the present invention or pharmacologically acceptable salts thereof are combined with pH adjusting agents, solubilizers, isotonizing agents, or such, and if needed, solubilizing agents, stabilizers, and such, and then formulated using routine methods.

Methods for producing external preparations are not limited, and they can be produced by conventional methods. Various conventional materials for pharmaceuticals, quasi-drugs, cosmetics, and such can be used as base materials in the production. Specifically, the base materials used include, for example, animal and vegetable oils, mineral oils, ester oils, waxes, higher alcohols, fatty acids, silicon oils, surfactants, phospholipids, alcohols, polyalcohols, water-soluble polymers, clay minerals, and purified water. Furthermore, as necessary, it is possible to add pH-adjusting agents, antioxidants, chelating agents, preservatives, colorants, flavoring agents, and such. However, the base materials for external preparations of the present invention are not limited thereto.

Furthermore, if needed, the preparations may be combined with components that have an activity of inducing differentiation, or components such as blood flow-enhancing agents, antimicrobial agents, antiphlogistic agents, cell-activating agents, vitamins, amino acids, humectants, and keratolytic agents. The amount of above-described base materials added is a quantity that provides a concentration typically selected in the production of external preparations.

The anticancer agents (granular pharmaceutical compositions for treating cancer) for administering a compound having FGFR inhibitory activity in the present invention are not particularly limited in their dosage form; and the agents may be administered orally or parenterally by commonly used methods. They can be formulated and administered as, for example, tablets, powders, granules, capsules, syrups, troches, inhalants, suppositories, injections, ointments, eye ointments, eye drops, nose drops, ear drops, cataplasms, lotions, etc.

In the present invention, the dosage of an FGFR inhibitor contained in an anticancer agent or a pharmaceutical composition for treating cancer can be appropriately selected according to the severity of symptoms, age, sex, weight, dosage form, salt type, specific type of disease, and such.

The dosage varies considerably depending on the patient's disease type, symptom severity, age, sex, sensitivity to the agent, and such. Typically, the agent is administered to an adult once or several times a day at a daily dose of about 0.03 to 1,000 mg, preferably 0.1 to 500 mg, and more preferably 0.1 to 100 mg. The agents or compositions of the present invention are administered once or several times a day. When an injection is used, the daily dose is generally about 1 μg/kg to 3,000 μg/kg, and preferably about 3 μg/kg to 1,000 μg/kg.

The present invention also relates to pharmaceutical compositions for treating cancer which comprise an above-described compound having FGFR inhibitory activity, and are characterized by their use of being administered to patients expressing a mutant polypeptide of the present invention or carrying a polynucleotide encoding the mutant polypeptide.

The present invention further relates to methods for treating or preventing cancer which comprise administering an effective amount of the above-mentioned compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof to patients expressing the mutant polypeptides or carrying the polynucleotides; use of compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof in the production of pharmaceutical compositions for cancer treatment for administration to patients expressing the fusion polypeptides or carrying the polynucleotides; compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof for use in treatment or prevention for patients expressing the mutant polypeptides or carrying the polynucleotides; and such.

Specifically, use of the pharmaceutical compositions for treating cancer is characterized in that whether a patient expresses the mutant polypeptide or carries a polynucleotide encoding the mutant polypeptide is tested using a mutant polypeptide of the present invention as a biomarker before an above-described anticancer agent comprising an FGFR inhibitor is administered to the patient, and the anticancer agent containing an FGFR inhibitor is administered to the patient only if the patient expresses the mutant polypeptide or carries a polynucleotide encoding the mutant polypeptide. This enables one to avoid side effects in therapies using the agent and control the therapeutic condition to produce the best therapeutic effect, thus enabling personalized medicine.

Whether a patient expresses a mutant polypeptide of the present invention or carries a polynucleotide encoding the mutant polypeptide can be tested by using methods of the present invention described above.

The present invention also relates to methods for identifying compounds having FGFR inhibitory activity.

Specifically, methods for identifying compounds having FGFR inhibitory activity in the present invention include methods comprising the steps of:

(a) culturing cells that express an above-described mutant polypeptide of the present invention in the presence or absence of a test compound and determining the level of cell proliferation; (b) comparing the proliferation level of cultured cell between in the presence and absence of the test compound; and (c) judging that the test compound has FGFR inhibitory activity when the proliferation level of the cell cultured in the presence of the test compound is lower than that of the cell cultured in the absence of the test compound.

Cells used for the above method may be primary cultured cells, established cell lines, or recombinant cells, as long as they express a mutant polypeptide of the present invention. Such recombinant cells include those introduced with an above-described vector carrying a polynucleotide encoding a mutant polypeptide of the present invention.

Meanwhile, the primary cultured cells include cells collected from cancer patients. The established cell lines include cancer cell lines established from cancer cells collected from cancer patients.

In the present invention, cancer includes any cancer described above.

Methods for identifying compounds having FGFR inhibitory activity in the present invention also include those comprising the steps of:

(a) administering a test compound to a non-human mammal transplanted with cells that express an above-described mutant polypeptide of the present invention and determining the proliferation level of the cells; (b) comparing the cell proliferation level determined in step (a) with that determined using a non-human mammal transplanted with the cells but not administered with the test compound; and (c) judging that the test compound has FGFR inhibitory activity when the cell proliferation level determined in step (a) is lower than that determined using a non-human mammal transplanted with the cells but not administered with the test compound.

Cells used for the above method may be primary cultured cells, established cell lines, or recombinant cells, as long as they express a mutant polypeptide of the present invention. Such recombinant cells include those introduced with an above-described vector carrying a polynucleotide encoding a mutant polypeptide of the present invention.

Meanwhile, the primary cultured cells include cells collected from cancer patients. The established cell lines include cancer cell lines established from cancer cells collected from cancer patients.

In the present invention, cancer includes any cancer described above.

In the methods of the present invention, the cell proliferation level can be tested according to routine methods, for example, by colorimetric methods that measure the enzyme activity of reducing a dye (MTT, XTT, MTS, WST, etc.) to formazan dye (purple).

When the above-described cells are cancer cells, the cell proliferation level can also be determined by measuring the volume or weight of tumor formed as a result of cell proliferation.

In the present invention, methods for identifying compounds having FGFR inhibitory activity also comprise embodiments that use reporter gene assays.

Reporter genes include commonly-used genes encoding arbitrary fluorescent proteins, for example, the green fluorescent protein (GFP) derived from Aequorea coerulescens , luciferase derived from Renilla reniformis or such, reef coral fluorescent proteins (RCFPs) derived from hermatypic coral, fruit fluorescent proteins, and variants thereof.

In the present invention, reporter gene assay can be carried out, for example, as follows.

Recombinant cells are prepared by transforming cells that are typically used for producing recombinant proteins with an expression vector inserted with a polynucleotide encoding the mutant polypeptide of the present invention and a gene encoding a reporter protein, so that the reporter protein-encoding gene is transcribed into mRNA dependently on the signal that transcribes the mutant polypeptide-encoding polynucleotide into mRNA. A test compound is contacted with the obtained transformed cells. Whether the compound affects the expression of the mutant polypeptide is indirectly analyzed by determining the expression level of the mutant polypeptide, which depends on the compound activity, by measuring the intensity of fluorescence emitted by the reporter protein simultaneously expressed with the mutant polypeptide (for example, U.S. Pat. Nos. 5,436,128; 5,401,629).

Identification of the compounds using the above-described assay can be achieved by manual operation; however, it can also be done readily and simply by so-called “high-throughput screening” using robots automatically (Soshiki Baiyou Kougaku (The Tissue Culture Engineering), Vol. 23, No. 13, p.521-524; U.S. Pat. No. 5,670,113).

Hereinbelow, the present invention is specifically described using the Examples, but it is not to be construed as being limited thereto.

Unless otherwise specified, each assay step can be performed according to known methods.

Meanwhile, when using commercially available reagents, kits, or such, assays can be performed according to manuals included in the commercial products.

All prior art documents cited herein are incorporated by reference in their entirety.

EXAMPLES [Example 1] Examination of the V564F Mutant and the V562L Mutant of FGFR2 (1) Evaluation of Phosphorylation-Inhibiting Actions by FGFR Inhibitors

The polynucleotide (SEQ ID NO: 6) encoding the FGFR2 V564F mutant (SEQ ID NO: 9) and the polynucleotide (SEQ ID NO: 7) encoding the FGFR2 V562L mutant (SEQ ID NO: 10) were prepared from the ORF polynucleotide (SEQ ID NO: 5) of the wild-type FGFR2 (SEQ ID NO: 8) by a PCR-based site-directed mutagenesis method. The wild-type FGFR2 ORF polynucleotide and a polynucleotide encoding the FGFR2 V564F mutant or the FGFR2 V562L mutant were subcloned into the pCXND3 vector (Kaketsuken) to prepare vectors for expressing each of the polypeptides. Each of the prepared vectors were introduced into HCT 116 human colon adenocarcinoma cells (ATCC) using a transfection reagent FuGENE® HD (Promega) to transiently express the wild-type FGFR2 polypeptide (SEQ ID NO: 8), the FGFR2 V564F mutant polypeptide (SEQ ID NO: 9), and the FGFR2 V562L mutant polypeptide (SEQ ID NO: 10), respectively. Either Compound A or Compound C was made to act on each of the cells in the presence of 0.1% DMSO, and then the cell lysates from each of the cells were collected by using Cell Lysis Buffer (Cell Signaling Technology). Analysis of each of the cell lysates by Western blotting using the Phospho-FGF Receptor (Tyr653/654) Antibody (Cell Signaling Technology) or the FGFR-2 Antibody (Sigma) revealed that the phosphorylation inhibitory effects of each compound on the FGFR2 V564F mutant polypeptide and the FGFR2 V562L mutant polypeptide showed a great reduction with Compound C, while the effects did not reduce much with Compound A, compared to the phosphorylation inhibitory effects on the wild-type FGFR2 polypeptide, as shown in FIG. 1.

(2) Evaluation of In Vitro Cell Proliferation-Inhibiting Effects by FGFR Inhibitors

Each polypeptide expression vector for the wild-type FGFR2, the FGFR2 V564F mutant, or the V562L mutant prepared in (1) of Example 1 was introduced into IL-3-dependent mouse pro-B cells Ba/F3 (Riken) by electroporation, the cells were cultured in the absence of IL-3 under conditions in which selection marker G-418 (Life Technology), and FGF1 (Sigma) and heparin (Sigma) was added, and then a Ba/F3 strain that can stably express the wild-type FGFR2 polypeptide, FGFR2 V564F mutant polypeptide, or FGFR2 V562L mutant polypeptide and can proliferate independently from IL-3 was established. Each of the strains seeded onto 96-well plates was added with each compound (Compound A, B, or C) made into a nine-step four-fold dilution series with the maximum concentration of 20 μM, or DMSO (used as the control), and cultured for four days. Cell proliferation after culturing for four days was measured using WST-8 (Dojindo Laboratories). Cell proliferation-inhibiting activity of each compound on each cell was calculated using the equation (1−T/C)×100 (%), where T is the absorbance value at 450 nm for a well wherein the cells were added with the compound of each concentration and cultured, and C is the absorbance value at 450 nm wherein the cells were added with DMSO and cultured, and the IC50 was calculated by the least-square method. As a result, the cell proliferation-inhibiting activities of each of the compounds on the strain stably expressing the FGFR2 V564F mutant polypeptide or the FGFR2 V562L mutant polypeptide was greatly weakened with Compound B and Compound C, while the activities showed hardly any change with Compound A, compared to their cell proliferation-inhibiting activities on the strain stably expressing the wild-type FGFR2 polypeptide, as shown in FIG. 2 and Table 2.

TABLE 2 IC50 RATIO RELATIVE TO WT FGFR2 COMPOUND COMPOUND COMPOUND MUTATION A B C V564F 1.9 90 37 V562L 0.58 3.2 3.5

[Example 2] Examination of the TEL-Fused FGFR2 V564F Mutant (1) Evaluation of In Vitro Cell Proliferation-Inhibiting Effects by FGFR Inhibitors

A polynucleotide encoding the dimerization domain of wild-type TEL (SEQ ID NO: 33) and a polynucleotide encoding the intracellular domain of wild-type FGFR2 (SEQ ID NO: 1) were fused by a PCR-based site-directed mutagenesis method to produce a polynucleotide (SEQ ID NO: 11) encoding the TEL-fused wild-type FGFR2 (SEQ ID NO: 34). Using the polynucleotide encoding the TEL-fused wild-type FGFR2 as a template, a polynucleotide (SEQ ID NO: 12) encoding the TEL-fused FGFR2 V564F mutant (SEQ ID NO: 35) was prepared by a PCR-based site-directed mutagenesis method. The polynucleotides encoding the TEL-fused wild-type FGFR2 and the TEL-fused FGFR2 V564F mutant were subcloned into a pCXND3 vector (Kaketsuken) to prepare vectors for expressing each of the polypeptides. Each polypeptide expression vector for the TEL-fused wild-type FGFR2 or the TEL-fused FGFR2 V564F mutant was introduced into IL-3-dependent mouse pro-B cells Ba/F3 by electroporation, and the cells were cultured in the absence of IL-3 with addition of selection marker G-418 to establish a Ba/F3 strain that can stably express the TEL-fused wild-type FGFR2 polypeptide or TEL-fused FGFR2 V564F mutant polypeptide and can proliferate independently of IL-3. Each of the strains seeded onto 96-well plates was added with each compound (Compound A, B, C, or E) made into an 18-step four-fold dilution series with the maximum concentration of 50 μM, a compound (Compound D) made into an 18-step four-fold dilution series with the maximum concentration of 10 μM, or DMSO (used as the control), and cultured for four days. Cell proliferation after culturing for four days was measured using WST-8 (Dojindo Laboratories). Cell proliferation-inhibiting activity of each compound on each cell was calculated using the equation (1−T/C)×100 (%), where T is the absorbance value at 450 nm for a well wherein the cells were added with the compound of each concentration and cultured, and C is the absorbance value at 450 nm wherein the cells were added with DMSO and cultured. As a result, the cell proliferation-inhibiting activities of each of the compounds on the strain stably expressing the TEL-fused FGFR2 V564F mutant polypeptide were greatly weakened with Compounds B, C, D, and E, while the activities showed hardly any change with Compound A, compared to their cell proliferation-inhibiting activities on the strain stably expressing the TEL-fused wild-type FGFR2 polypeptide, as shown in FIG. 3.

(2) Evaluation of In Vivo Tumor Increase-Inhibiting Effects by FGFR Inhibitors

The Ba/F3 strain established in (1) of Example 2 that can stably express the TEL-fused wild-type FGFR2 polypeptide or the TEL-fused FGFR2 V564F mutant polypeptide and which can proliferate independently of IL-3, was inoculated subcutaneously in the inguinal region of BALB/c nude mice (Japan Charles River) with 5.0×10⁶ to 5.2×10⁶ cells per inoculation. From nine days after the inoculation, Compound A or Compound C suspended in a solution containing 10% DMSO, 10% Cremophor EL, 15% PEG400, and 15% HPCD, was administered orally once every day to the mice at a concentration of 20 mL/kg. As shown in FIG. 4, the tumor proliferation-inhibiting activities of each of the compounds in mice carrying tumor cells that express the TEL-fused FGFR2 V564F mutant polypeptide showed a great reduction with Compound C, while the activities showed hardly any change with Compound A, compared to the activities in mice carrying tumor cells expressing the TEL-fused wild-type FGFR2 polypeptide.

Furthermore, tumor lysates were collected from tumor samples that have undergone the testing, by using a Cell Lysis Buffer (Cell Signaling Technology), and each of the tumor lysates were analyzed by Western blotting using Phospho-FGF Receptor (Tyr653/654) Antibody (Cell Signaling Technology) or FGFR-2 Antibody (Sigma). As shown in FIG. 5, the inhibitory effects of each of the compounds on phosphorylation in tumors in mice carrying tumor cells that express the TEL-fused FGFR2 V564F mutant polypeptide showed a great reduction with Compound C, while the activities showed hardly any change with Compound A, compared to the activities in mice carrying tumor cells expressing the TEL-fused wild-type FGFR2 polypeptide.

INDUSTRIAL APPLICABILITY

The mutant FGFR polypeptides of the present invention demonstrate resistance to known FGFR inhibitors such as AZD4547, and at the same time demonstrate sensitivity to specific compounds. Therefore, the mutant polypeptides may be used as biomarkers in cancer treatment by various FGFR inhibitors to determine applicability of each type of FGFR inhibitor to each individual patient, to prevent the development of side effects in therapy using conventional FGFR inhibitors, and to control the therapeutic mode for receiving the best therapeutic effect, thus making individualized treatment possible. 

1. A pharmaceutical composition for cancer treatment comprising as an active ingredient the compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition for cancer treatment is characterized in being used by administering it to a patient expressing an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7^(th) amino acid from the N terminus and/or a substitution of valine to leucine at the 5^(th) amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide, or having a polynucleotide encoding said mutant polypeptide:

wherein R₁, R₂, R₃, and R₄ each independently represents the group listed below: R₁ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C2-6 alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_(n)Z₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃; R₂ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_(n)Z₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃; or R₁ and R₂, together with an atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl, wherein the heterocyclyl or heteroaryl is optionally substituted by halogen; R₃ represents methyl; R₄ represents hydrogen; A is indole; R₅ represents C₁₋₅ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₃ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₁₋₃ alkoxy C₁₋₄ alkoxy C₁₋₄ alkyl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl C₁₋₃ alkyl, or 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, or C₁₋₆ trihydroxy alkyl which is optionally substituted by one or more groups independently selected from group Q; R₆ and R₇, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₃ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, C₁₋₆ trihydroxy alkyl, 3- to 10-membered heterocyclyl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, or cyano(C₁₋₃ alkyl); or alternatively R₆ and R₇, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; n represents 1 to 3; R₈ and R₉, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, or halogen; or alternatively R₈ and R₉, together with a carbon atom linked thereto, form a cycloaliphatic ring; Z₁ represents hydrogen, NR₁₀R₁₁, —OH, or 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q; R₁₀ and R₁₁, which can be the same or different, each represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, cyano(C₁₋₃ alkyl), or C₁₋₃ alkylsulfonyl C₁₋₄ alkyl; or alternatively R₁₀ and R₁₁, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R₁₂ and R₁₃, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, 3- to 10-membered cycloaliphatic ring, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; or alternatively R₁₂ and R₁₃, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q; R₁₄ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₅ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₆ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₇ represents hydrogen or C₁₋₄ alkyl; R₁₈ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₁₉ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, haloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R₂₉ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₁ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₂ represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl; R₂₃ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₄ represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl; R₂₅ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₂₆ and R₂₇, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxyl C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively R₂₆ and R₂₇, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R₂₈ and R₂₉, which can be the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxyl C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocyclyl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively R₂₈ and R₂₉, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R₃₀ represents C1-4 alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₃₁represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R₃₂ represents C₁₋₄ alkyl or C₆₋₁₀ aryl; <group P> halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, 3- to 10-membered heterocyclylamino, —SO₂R₁₆, —CN, —NO₂, and 3- to 10-membered heterocyclyl; <group Q> halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₆ monohydroxy alkyl, C1_6 dihydroxy alkyl, C₁₋₆ trihydroxy alkyl, 3- to 10-membered heterocyclyl amine, —SO₂R₁₆, —CN, —NO₂, C₃₋₇ cycloalkyl, —COR₁₉, and 3- to 10-membered heterocyclyl which is optionally substituted by C₁₋₄ alkyl.
 2. The pharmaceutical composition of claim 1, comprising as an active ingredient the compound represented by the formula below or a pharmaceutically acceptable salt thereof:


3. An FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7^(th) amino acid from the N terminus and/or a substitution of valine to leucine at the 5^(th) amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide.
 4. A polynucleotide encoding the mutant polypeptide of claim
 3. 5. A vector comprising the polynucleotide of claim
 4. 6. A recombinant cell comprising the vector of claim
 5. 7. An antibody, or antigen-binding fragment thereof, that specifically binds to the mutant polypeptide of claim
 3. 8. A pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of claim 3 for detecting or amplifying the polynucleotide.
 9. An oligonucleotide that binds to an mRNA polynucleotide encoding the mutant polypeptide of claim 3 and has an activity to inhibit translation of the mRNA polynucleotide into protein.
 10. The oligonucleotide of claim 9, which is an siRNA that cleaves the mRNA polynucleotide.
 11. A method for detecting an FGFR mutant polypeptide, which comprises the step of detecting the mutant polypeptide in a sample isolated from a subject by using an antibody, or antigen-binding fragment thereof, that specifically binds to the mutant polypeptide of claim
 3. 12. A method for detecting a polynucleotide encoding an FGFR mutant polypeptide, which comprises the step of detecting a polynucleotide encoding the mutant polypeptide in a sample isolated from a subject by using a pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of claim 3 for detecting or amplifying the polynucleotide.
 13. A kit for detecting a polynucleotide encoding an FGFR mutant polypeptide, which comprises a pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of claim 3 for detecting or amplifying the polynucleotide.
 14. A kit for detecting an FGFR mutant polypeptide, which comprises an antibody or antigen-binding fragment thereof that specifically binds to the mutant polypeptide of claim
 3. 15. A method for treating cancer, which comprises determining the presence or absence of the mutant polypeptide of claim 3 or a polynucleotide encoding the mutant polypeptide in a sample isolated from a subject and administering the pharmaceutical composition of claim 1 or 2 to the subject when the mutant polypeptide or the polynucleotide is detected.
 16. The method of claim 15, wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell carcinoma, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer.
 17. A method for selecting a patient to which the pharmaceutical composition of claim 1 or 2 is applicable, which comprises the steps of: (a) determining the presence or absence of the mutant polypeptide of claim 3 in a sample isolated from a subject; and (b) selecting a subject confirmed to have the mutant polypeptide as a patient to which the pharmaceutical composition is applicable.
 18. A method for selecting a patient to which the pharmaceutical composition of claim 1 or 2 is applicable, which comprises the steps of: (a) determining the presence or absence of a polynucleotide encoding the mutant polypeptide of claim 3 in a sample isolated from a subject; and (b) selecting a subject confirmed to have a polynucleotide encoding the mutant polypeptide as a patient to which the pharmaceutical composition is applicable.
 19. The method of claim 18, wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell carcinoma, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer.
 20. The compound defined in claim 1 or 2 or a pharmaceutically acceptable salt thereof for use in cancer treatment in a patient who expresses the mutant polypeptide of claim 3 or has a polynucleotide encoding the mutant polypeptide.
 21. The compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell cancer, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer.
 22. A pharmaceutical composition for cancer treatment comprising as an active ingredient the compound represented by the formula below or a pharmaceutically acceptable salt thereof, wherein the cancer expresses an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7^(th) amino acid from the N terminus and/or a substitution of valine to leucine at the 5^(th) amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide:


23. A pharmaceutical composition for cancer treatment comprising as an active ingredient a substance that inhibits the function or expression of an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7^(th) amino acid from the N terminus and/or a substitution of valine to leucine at the 5^(th) amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide. 